

FORM PTG-1390 (REV 11-2000)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER <b>163-34</b>
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) <b>09/913329</b> Unassigned
INTERNATIONAL APPLICATION NO. PCT/CA00/09147	INTERNATIONAL FILING DATE 11 February 2000	PRIORITY DATE CLAIMED 11 February 1999
TITLE OF INVENTION <b>NEW METALLOPROTEASES OF THE NEPRILYSIN FAMILY</b>		
APPLICANT(S) FOR DO/EO/US <b>DESGROSEILLERS et al</b>		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input type="checkbox"/> The U.S. has been elected by the expiration of 19 months from the priority date (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)). a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has <b>NOT</b> expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> A English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).		
<b>Items 11 To 20 below concern document(s) or information included:</b>		
11. <input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input type="checkbox"/> Other items or information.		

U.S. APPLICATION NO. (Under 37 C.F.R. 1.5) <b>09/913329</b> <b>unassigned</b>		INTERNATIONAL APPLICATION NO. <b>PCT/CA00/00147</b>		ATTORNEY'S DOCKET NUMBER <b>163-34</b>	
---	--	--	--	---	--

21. <input checked="" type="checkbox"/> The following fees are submitted:					<b>CALCULATIONS</b> PTO USE ONLY	
<b>BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5)):</b> -- Neither international preliminary examination fee (37 C.F.R. 1.482) nor international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO .....\$1000.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO.....\$860.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO .....\$710.00 -- International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$690.00 -- International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4).....\$100.00						
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>					\$	1000.00
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).					\$	130.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE			
Total Claims	38	-20 =	18	X	\$18.00	\$ 324.00
Independent Claims	8	-3 =	5	X	\$80.00	400.00
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)					\$270.00	\$ 0.00
<b>TOTAL OF ABOVE CALCULATIONS =</b>					\$	<b>1854.00</b>
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.						927.00
<b>SUBTOTAL =</b>					\$	<b>927.00</b>
Processing fee of \$130.00, for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(f)).					+	0.00
<b>TOTAL NATIONAL FEE =</b>					\$	<b>927.00</b>
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). <b>\$40.00</b> per property					+	0.00
Fee for Petition to Revive Unintentionally Abandoned Application (\$1240.00 - Small Entity = \$620.00)					\$	0.00
<b>TOTAL FEES ENCLOSED =</b>					\$	<b>927.00</b>
					Amount to be:	
					refunded	\$
					Charged	\$


  

a. ☒ A check in the amount of \$927.00 to cover the above fees is enclosed.  
 b. ☐ Please charge my Deposit Account No. 14-1140 in the amount of \$\_\_\_\_\_ to cover the above fees.  
     A duplicate copy of this form is enclosed.  
 c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A duplicate copy of this form is enclosed.  
 d. ☒ The entire content of the foreign application(s), referred to in this application is/are hereby incorporated by reference in this application.

**NOTE:** Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

**SEND ALL CORRESPONDENCE TO:**

NIXON & VANDERHYE P.C.  
 1100 North Glebe Road, 8<sup>th</sup> Floor  
 Arlington, Virginia 22201-4714  
 Telephone: (703) 816-4000

  
 SIGNATURE

NAME \_\_\_\_\_  
 August 13, 2001  
 REGISTRATION NUMBER \_\_\_\_\_ Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

DESGROSEILLERS et al

Atty. Ref.: 163-34

Serial No. Unassigned

Group:

Filed: August 13, 2001

Examiner:

For: NEW METALLOPROTEASES OF THE NEPRILYSIN FAMILY

\* \* \* \* \*

August 13, 2001

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**PRELIMINARY AMENDMENT**

Please amend the above application as follows:

**IN THE CLAIMS**

Please substitute the following amended claims for corresponding claims previously presented. A copy of the amended claims showing current revisions is attached.

**REMARKS**

The above amendments have been made to place the application in a more traditional format.

5. (Amended) A composition comprising a metallopeptidase as defined in claim 2.

6. (Amended) A nucleic acid encoding a metallopeptidase as defined in claim 2.

7. (Amended) An antibody directed against a metallopeptidase as defined in claim 2.

8. (Amended) A method for obtaining a substrate of a metallopeptidase as defined in claim 2, which comprises the steps of:

- contacting said metallopeptidase with a molecule or extract; and
- assaying the resulting solution for a decrease in said molecule or extract, when compared with the same but in absence of said metallopeptidase, as an indication of the presence of said substrate.

9. (Amended) A method for obtaining an inhibitor of a metallopeptidase as defined in claim 2, which comprises the steps of:

contacting said metallopeptidase with a molecule or extract in the presence of a substrate selected known NEP substrates, preferably Tyrosyl-[3,5-<sup>3</sup>H1](D-Ala<sub>2</sub>)-Leu<sub>5</sub>-enkephalin and bradykinin; and

-- assaying the resulting solution for an increase in said substrate, when compared with the same but in absence of said metallopeptidase, as an indication of the presence of said inhibitor.

11. (Amended) The use of a known NEP inhibitor or an inhibitor as defined in claim 10 to control the enzymatic activity of a metallopeptidase as defined above.

13. (Amended) The use of a metallopeptidase as defined in claim 2 to manage disease relating to the physiological status of the cardiovascular system, the central nervous system, the spleen, the liver, the kidney, the male reproductive system or the maturation of spermatozoa.

19. (Amended) A composition comprising a metallopeptidase as defined in claim 16.

20. (Amended) A nucleic acid encoding a metallopeptidase as defined in claim 16.

21. (Amended) An antibody directed against a metallopeptidase as defined in claim 16

22. (Amended) A method for obtaining a substrate of a metallopeptidase as defined in claim 18, which comprises the steps of:

- contacting said metallopeptidase with a molecule or extract; and
- assaying the resulting solution for a decrease in said molecule or extract, when compared with the same but in absence of said metallopeptidase, as an indication of the presence of said substrate.

23. (Amended) A method for obtaining an inhibitor of a metallopeptidase as defined in claim 16, which comprises the steps of:

- contacting said metallopeptidase with a molecule or extract in the presence of a substrate selected from known NEP substrates or a protein. polypeptide or part thereof produced by the method of claim 15, preferably Tyrosyl-[3,5-<sup>3</sup>H1](D-Ala<sub>2</sub>)-Leu<sub>5</sub>-enkephalin and bradykin in; and
- assaying the resulting solution for an increase in said substrate, when compared with the same but in absence of said metallopeptidase, as an indication of the presence of said inhibitor.

25. (Amended) The use of a known NEP inhibitor or an inhibitor as defined in claim 24 to control the enzymatic activity of a metallopeptidase as

defined above claim 16.


27. (Amended) The use of a metallopeptidase as defined in claim 16 to manage disease relating to the physiological status of the cardiovascular system, the central nervous system, the spleen, the liver, the kidney, the male reproductive system or the maturation of spermatozoa.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached pages are captioned "**Version With Markings To Show Changes Made.**"

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_

  
Leonard C. Mitchard  
Reg. No. 29,009

LCM:lks  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE CLAIMS**

5. (Amended) A composition comprising a metallopeptidase as defined in [any one of claims 2-4] claim 2.

6. (Amended) A nucleic acid encoding a metallopeptidase as defined in [any one of claims 2-4] claim 2.

7. (Amended) An antibody directed against a metallopeptidase as defined in [any one of claims 2-4] claim 2.

8. (Amended) A method for obtaining a substrate of a metallopeptidase as defined in [any one of claims 2-4] claim 2, which comprises the steps of:

-- contacting said metallopeptidase with a molecule or extract; and  
-- assaying the resulting solution for a decrease in said molecule or extract, when compared with the same but in absence of said metallopeptidase, as an indication of the presence of said substrate.

9. (Amended) A method for obtaining an inhibitor of a metallopeptidase as defined in [any one of claims 2-4] claim 2, which comprises



the steps of:

contacting said metallopeptidase with a molecule or extract in the presence of a substrate selected known NEP substrates, preferably

Tyrosyl-[3,5-<sup>3</sup>H1)(D-Ala<sub>2</sub>)-Leu<sub>5</sub>-enkephalin and bradykinin; and

-- assaying the resulting solution for an increase in said substrate, when compared with the same but in absence of said metallopeptidase, as an indication of the presence of said inhibitor.

11. (Amended) The use of a known NEP inhibitor or an inhibitor as defined in claim 10 to control the enzymatic activity of a metallopeptidase as defined [in any one of claims 2-4] above.

13. (Amended) The use of a metallopeptidase as defined in [any one of claims 2-4] claim 2 to manage disease relating to the physiological status of the cardiovascular system, the central nervous system, the spleen, the liver, the kidney, the male reproductive system or the maturation of spermatozoa.

19. (Amended) A composition comprising a metallopeptidase as defined in [any one of claims 16-18] claim 16.

20. (Amended) A nucleic acid encoding a metallopeptidase as defined in [any one of claims 16-18] claim 16.

21. (Amended) An antibody directed against a metallopeptidase as defined in [any one of claims 16-18] claim 16

22. (Amended) A method for obtaining a substrate of a metallopeptidase as defined in [anyone of claims 16-18] claim 18, which comprises the steps of:

- contacting said metallopeptidase with a molecule or extract; and
- assaying the resulting solution for a decrease in said molecule or extract, when compared with the same but in absence of said metallopeptidase, as an indication of the presence of said substrate.

23. (Amended) A method for obtaining an inhibitor of a metallopeptidase as defined in [any one of claims 16-18] claim 16, which comprises the steps of:

- contacting said metallopeptidase with a molecule or extract in the presence of a substrate selected from known NEP substrates or a protein. polypeptide or part thereof produced by the method of claim 15, preferably Tyrosyl-[3,5-<sup>3</sup>H1](D-Ala<sub>2</sub>)-Leu<sub>5</sub>-enkephalin and bradykin in; and
- assaying the resulting solution for an increase in said substrate, when compared with the same but in absence of said metallopeptidase, as an indication of the presence of said inhibitor.

25. (Amended) The use of a known NEP inhibitor or an inhibitor as defined in claim 24 to control the enzymatic activity of a metallopeptidase as defined above [in any one of claims 16-18] claim 16.

27. (Amended) The use of a metallopeptidase as defined in [any one claims 16-18] claim 16 to manage disease relating to the physiological status of the cardiovascular system, the central nervous system, the spleen, the liver, the kidney, the male reproductive system or the maturation of spermatozoa.

**TITLE OF THE INVENTION**New Metalloproteases of the Neprilysin Family**BACKGROUND OF THE INVENTION**

5           Peptides are used by cells from yeast to mammals to elicit physiological responses. The use of peptides as messengers usually involves the following steps: 1) production and release of the peptide by a specific cell, 2) interaction of the peptide with a receptor on the surface of the target cell, and 3) degradation of the peptide to terminate its action. The first and last steps of this scheme require the participation of

10           proteases/peptidases. There is increasing evidence that membrane-associated zinc-metallopeptidases play important roles in both of these steps. Although activation of prohormone precursors into bioactive peptides is generally performed by proteases of the subtilisin family located in the *Trans*-Golgi Network or in secretory granules of the cell (for a review see: (Seidah and Chrétien, 1995)) a few peptides need a final

15           processing step. This step involves the action of membrane-associated zinc-metallopeptidases. Two cases are particularly well documented: angiotensin-converting enzyme (ACE) which cleaves inactive angiotensin I into angiotensin II (Corvol and Williams, 1997) and endothelin-converting enzymes (ECEs) which cleave isoforms of big endothelins into endothelins (Turner, 1997a). In addition to their role

20           in peptide activation, cell surface zinc-metallopeptidases have also been implicated in the termination of the peptidergic signal by breaking down the active peptides into inactive fragments. One of the best known of these peptidases is probably Neutral Endopeptidase-24.11 (Neprilysin, NEP) that has been implicated in the physiological degradation of several bioactive peptides (Kenny, 1993). Interestingly, NEP and the

25           ECEs show significant structural similarities and appear to be members of a family of peptidases that also includes PEX, a newly discovered and not yet characterized peptidase, and the KELL blood group protein (Turner and Tanzawa, 1997b). Because of their important role as regulators of bioactive peptide activity, these enzymes (more specifically NEP and the ECEs) have been identified as putative targets for therapeutic

30           intervention, similar to the way ACE inhibitors are used to control blood pressure. The recent discovery of PEX, another member of the family, which appears to be involved in phosphate homeostasis, raised the possibility that other yet unknown members might exist.

35           Members of the NEP-like family are type II membrane proteins consisting of three distinct domains: a short NH<sub>2</sub>-terminal cytosolic sequence, a single transmembrane region, and a large extracellular or ectodomain responsible for the catalytic activity of the enzyme. There are potential N-glycosylation sites and cysteine residues that are involved in disulfide bridges stabilizing the conformation of the active enzyme. These enzymes are metalloenzymes with a Zn atom in their active site. As

such, they belong to the zincin family of peptidases which is characterized by the active site consensus sequence HEXXH (Hooper, 1994), where the two histidine residues are zinc ligands. In members of the NEP-like family of peptidases, the third zinc ligand is a glutamic acid residue located on the carboxy-terminus side of the consensus sequence. This characteristic puts them in the gluzincin sub-family (Hooper, 1994). The model enzyme for gluzincins is thermolysin (TLN) a bacterial protease whose 3D structure has been determined by X-ray crystallography (Holmes and Matthews, 1982). The active site of NEP has been extensively studied by site-directed mutagenesis and several residues involved in zinc binding (Devault et al., 1988b; Le Moual et al., 1991; Le Moual et al., 1994), catalysis (Devault et al., 1988a; Dion et al., 1993), or substrate binding (Vijayaraghavan et al., 1990; Beaumont et al., 1991; Dion et al., 1995; Marie-Claire et al., 1997) have been identified (for a recent review see Crine et al., 1997).

## **SUMMARY OF THE INVENTION**

Here, we developed an RT-PCR strategy to look for other members of this important family of peptidases. This strategy allowed the molecular cloning and characterization of three additional NEP-like (NL) metallopeptidases (called NL-1, NL-2 and NL-3). Knowledge obtained through these studies allows the generation of reagents (nucleic acid probes and primers, antibodies and active recombinant enzymes) for further biochemical characterization of these enzymes and their pattern of expression and will greatly help the rational design of specific inhibitors that could be used as therapeutic agents.

Accordingly, the present invention relates to the following products:

- A. Degenerate primers for screening new NEP-related enzymes;
- B. NL-1, NL-2 and NL-3 proteins as NEP-related enzymes;
- C. Nucleic acids encoding these enzymes;
- D. Antibodies directed against the enzymes;
- E. Recombinant vectors comprising the nucleic acids encoding the enzymes and hosts transformed therewith;
- F. Fragments of the nucleic acids useful as probes or primers to hybridize and detect the presence of an NL-1, NL-2 and NL-3 genes, or to hybridize and amplify and produce gene fragments;
- G. Soluble forms of NL-1, NL-2 and NL-3; and
- H. Nucleic acids comprising the N-terminal part of NL-1 or NL-2 which terminates with a sequence encoding a furin recognition site, such nucleic acids being useful for making a fusion protein with the ectodomain of any protein of interest, and for releasing a soluble form of that protein of interest (containing the ectodomain) in the medium.

Also the present invention relates to the following methods:

- A. A method for screening NEP-related enzymes that make use of degenerate primers or probes selected from a region of NEP family members in a highly conserved region, namely around the zinc-binding sites; and
- 5 B. A method for producing NL-1, NL-2 or NL-3 that includes the steps of culturing the above recombinant host and recovering NL-1, NL-2 and NL-3 gene products therefrom.

10 The present invention will be described hereinbelow by referring to specific embodiments and appended figures, which purpose is to illustrate the invention rather than to limit its scope.

In the first section, general procedures leading to the identification and localization of NL-1, NL-2 and NL-3 are given. In the second section, slightly different procedures are given for completing or reiterating the work performed on NL-1.

15

### **BRIEF DESCRIPTION OF THE FIGURES**

**Figure 1:** Amino acid sequence comparison of human NEP, PEX, KELL and ECE1 peptidases. Amino acid sequences in boxes are those used to design the oligonucleotide primers. Numbers and arrows under the sequences identify the primer and its orientation.

20

**Figure 2:** Sequences of the oligonucleotide primers used in the PCR reactions.

**Figure 3:** Nucleotide and amino acid sequence of the mouse NL-1 cDNA. The sequence of the DNA fragment obtained by PCR is in brackets.

**Figure 4:** Partial nucleotide and amino acid sequence of the human NL-2 cDNA. The sequence of the DNA fragment obtained by PCR is in brackets.

25

**Figure 5:** Partial nucleotide and amino acid sequence of the human NL-3 cDNA.

**Figure 6:** Amino acid sequence comparison of NEP, NL-1, NL-2 and NL-3 peptidases.

30

**Figure 7:** *In situ* hybridization of mouse testis sections using NL-1 as a probe.

**Figure 8:** *In situ* hybridization of mouse sections using mouse NL-3 as a probe.

**Figure 9:** *In situ* hybridization of mouse spinal chord sections

**Figure 10:** Expression of NL-1 in mammalian cells.

**Figure 11:** Activity of recombinant soluble NL-1.

35

**Figure 12:** Expression of a soluble form of NL-3 using NL-1 amino-terminal domain.

## DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION

### SECTION 1)

#### 5 MATERIALS AND METHODS

##### DNA and RNA manipulations

All DNA manipulations and Northern blot analysis were performed according to standard protocols (Ausubel et al., 1988; Sambrook et al., 1989).

##### mRNA purification and cDNA synthesis

10 mRNAs were prepared from mouse testis using Quick Prep Micro mRNA purification kit (Pharmacia Biotech). Purified mRNAs were kept at -70° until ready used. First strand cDNA was synthesized from 1 µg of mRNA using the First-Strand cDNA synthesis kit (Pharmacia Biotech). The human testis cDNA library was obtained from Clontech.

##### 15 Polymerase chain reaction protocol

PCR was performed in a DNA thermal cycler with 5 µl of cDNA template and 1 µl of Taq DNA polymerase in a final volume of 100 µl, containing 1 mM MgCl<sub>2</sub>, 2 µM of each primer oligonucleotide, 20 µM of each dNTP and 5% DMSO. Cycling profiles included an initial denaturation step of 5 min at 94°C, followed by 30 cycles of 1 min at 94°C, 1 min at 40°C and 1.5 min at 72°C. A final extension step was performed at 72°C for 10 min. The amplified DNA was loaded on a 2% agarose gel and visualized by staining with ethidium bromide. Fragments ranging in size between 500-700 bp were cut and eluted from the gel. If needed, a second round of PCR was done with nested oligonucleotide primers, using 10 µl of the first PCR reaction, or of the eluted band cut from the agarose gel. Resulting fragments were ligated in pCR2.1 vector (Invitrogen) according to the distributor's recommendations. DH5α *Escherichia coli* cells were transformed with the ligation mixture and grown on 2YT plates in the presence of kanamycin. Plasmids were prepared from resistant cells and sequenced.

##### 25 In situ hybridization on mouse tissues and chromosomal localization of human genes

30 *In situ* hybridization on whole mouse slices or isolated tissues was performed as described previously (Ruchon et al., 1998).

To determine the chromosomal localization of human NL-2 and NL-3 genes, a technique for mapping genes directly to banded human chromosomes was used. Metaphase chromosomes were obtained from lymphocytes cultured from normal human peripheral blood. Cells were synchronized with thymidine and treated with 5-bromodeoxyuridine (BrdU) during the last part of the S phase to produce R-banding. Biotin-labeling of the probe was done by nick-translation (Bionick, BRL) and the probe was visualized by indirect immunofluorescence.

##### 35 Antibody production

TO 230 62260

To raise antibodies against the new peptidases, the cDNA sequences of each protein was compared to that of other members of the family and the sequence segment showing the less homology was used. These sequences are from amino acid residues 273 to 354 for NL-1, from 75 to 209 for NL-2 and from 143 to 465 for NL-3.

- 5 These cDNA fragments were cloned in vector pGEX2T (Pharmacia Biotechnology) downstream from and in phase with Glutathione-S-transferase (GST). Plasmids were transformed in *E. coli* strain AP401 and, induction of synthesis and purification of the fusion proteins were performed as recommended by the supplier. The NL polypeptides were cleaved from the fusion protein with thrombin and purified by SDS-PAGE.
- 10 polypeptides were injected to rabbits or mice according to the following schedules: for rabbits, initial injection of 150 µg of protein with boosts of the same amount 4 weeks and 8 weeks following the initial injection; for mice, initial injection of 100 µg of protein followed by boosts of the same amounts 3 and 6 weeks later. A month after the last injection, sera were collected from the animals and tested by immunoblotting against
- 15 the initial *E. coli*-produced antigens and the recombinant proteins produced in mammalian cell lines.

#### Production of monoclonal antibodies

- cDNA fragments corresponding to amino acids segments of NLs selected to raise antibodies were used to construct a GST-fusion protein in *E. coli*. This fusion protein
- 20 was purified from *E. coli* extracts by affinity chromatography on a glutathione-Sepharose column according to the supplier's instructions (Amersham-Pharmacia). After thrombin cleavage, the NL portion of the GST fusion protein was further purified by electroelution from a polyacrylamide gel. This material was used to immunise 4 mice (5 injections of ≈50 µg of NL polypeptide). Blood was collected from each mice
- 25 after the immunisation schedule and the presence of antibodies in mice serum was assessed by ELISA using microtiter plates coated with NL polypeptide from *E. coli* extracts. Mice sera were also tested for the presence of NL antibodies by Western blotting extracts of mammalian cells transfected with the NL expression vectors. One mouse selected for its high titer of NL specific antibodies (as measured by ELISA) was
- 30 sacrificed and its spleen cells were collected and immortalised by fusion with myeloma cells (strain: P3-X63Ag.653 from ATCC) as described previously (Crine 1985). Hybridoma cells were selected for their ability to grow in HAT selection medium and cloned by several rounds of limiting dilution. Hybridomas showing proper affinity and specificity to the enzymes NL-1, NL-2 and NL-3 where selected.

35

#### Expression of NLs in cultured mammalian cells and enzymatic assays

The cDNAs for NL-1 and NL-3 were cloned in vectors pcDNA3 or pRcCMV (Invitrogen) and introduced by transfection in mammalian cell lines according to procedures already described in our laboratory (Devault *et al.*, 1988a). Procedures to



prepare extracts of cellular proteins or culture media were also described in previous papers (Devault *et al.*, 1988a; Lemay *et al.*, 1989). The presence of NLs in these extracts was monitored by immunoblotting using specific antibodies.

5 Extracts of cellular proteins and culture media were assayed for enzymatic activity. Two tests were performed. The first used [<sup>3</sup>H]-Tyr-(D)Ala<sub>2</sub>-Leu-enkephalin as substrate and was performed according to Lemay *et al.*, (1989). The second used bradykinin as substrate and was performed as described by Raut *et al.* (1999).

## RESULTS

### 10 Cloning of NL-1, a new member of the NEP family

The molecular cloning in the past few years of ECEs, PEX and KELL showed that all these proteins have between 50 and 60% similarity with NEP. This observation led us to believe that these peptidases are part of an extended family and that there could be still additional members to be discovered. To test this hypothesis, we aligned  
15 the amino acid sequences of the members of the NEP-like family and designed degenerate oligonucleotide primers to be used in RT-PCR reactions (Figure 1 and 2). These primers were located on either side of the HEXXH consensus sequence for zincins. Because they are highly degenerate, primers 1 and 2 were each subdivided into two pools, 1A-1B, and 2A-2B, respectively (Figure 2). Any PCR amplified DNA  
20 fragment that corresponds to a peptidase of the family should normally contain the consensus sequence and be easily recognized by sequencing of the cloned fragments. Using this strategy, we first performed PCR reactions with primer pairs 1A-3 and 1B-3. The amplified DNA migrates mostly as a smear starting at around 700 bp and going down to 100 bp. As the expected fragments should be around 550 bp, we isolated from  
25 the gel the section corresponding to DNA fragments longer than 500 bp. A second round of PCR reactions was performed with both crude PCR products of the first reaction and isolated DNA bands, using primers 2A-3 and 2B-3. The expected 296 bp fragment was seen on the gel (not shown).

Cloning of these DNA fragments generated approximately 350 clones, of which  
30 44 were sequenced. Nine of these had no inserts or corresponded to sequences not related to the NEP family, 24 corresponded to NEP, 3 to PEX, and 8 corresponded to one putative new member of the family, since they all contained the HEXXH consensus sequence for zincins and showed 65% homology with mouse NEP (in boxes Figure 3). This fragment was then used to screen a mouse testis cDNA library,  
35 and allowed us to isolate a complete cDNA of 2592 nucleotides (Figure 3). The identity of this sequence with other members of the family is presented in Table I. This new member was called NL-1, for NEP-like peptidase 1.

### Cloning of NL-2 and NL-3.

A strategy similar to that described for amplification of enzymes of the NEP family from mouse testis cDNAs was used with a human testis cDNA library using two different oligonucleotide primers. This time, DNA fragments of approximately 900 bp were obtained and cloned. Ten clones were sequenced, revealing the presence of NEP and two new peptidases of the family that we have called NL-2 and NL-3.

The NL-2 PCR fragment was 879 nucleotides in length and encoded a 293 amino acid residue segment probably located in the carboxy-terminal domain of this putative peptidase (in brackets Figure 4). This PCR fragment was then used to screen a lambda gt10 human brain cDNA library. It allowed the isolation of other cDNA fragments which overlap partially with the NL-2 PCR fragment. Fusion of these lambda clones and the PCR fragment resulted in an open reading frame of 770 amino acid residues. The use of 5' RACE protocols with human testis cDNA libraries allowed completion of the sequence of NL-2 ORF (Figure 4). This ORF codes for a putative protein that is about 80% identical to the mouse NL-1 protein (Figure 6). Across species, members of the NEP, PEX, ECEs sub-families have highly conserved sequences (more than 94% identity). Although a sequence identity of about 80% only exists between the novel human protein and mouse NL-1, these proteins share unique characteristics that make possible the fact that NL-2 protein may be the human homologue of NL-1. The identity of NL-2 with other members of the family is presented in Table I.

The 879 bp PCR fragment encoding NL-3 showed an open reading frame of 293 amino acid residues (Figure 5, in brackets). Sequence analysis of NL-3 showed that it was 94.2 % identical to an EST sequence from mouse embryonic tissue present in publicly accessible DNA data banks. This mouse EST sequence, commercially available from American Tissue and Cell Culture (ATCC), had been obtained previously by our laboratories.

Since Northern blot analysis of human tissues with the NL-3 PCR fragment showed the expression of this protein in spinal chord (see below), the same PCR DNA fragment was used to screen by hybridization a human spinal chord cDNA library constructed in phage  $\lambda$  vectors. One clone contained a full-length ORF of 752 amino acid residues that encompassed the 293 amino acid residue ORF of the PCR fragment. Further probing, cloning and sequencing lead to the obtention of NL-3 full sequence, shown in Figure 5.

Figure 6 presents a comparison of the amino acid sequence of the new NEP-like enzymes and Table I shows the extent of identity between members of the family.

### Cellular distribution of NL-1, NL-2 and NL-3 peptidases

Determining the tissue distribution of NL-1, NL-2 and NL-3 may provide clues to identify the peptidergic systems in which they are involved. It will be particularly

interesting to compare the tissue distribution of these peptidases with that of NEP and the ECEs to determine whether or not the physiological functions of NL-1 and/or NL-2 and/or NL-3 may overlap those of NEP and/or ECEs.

5 *In situ* hybridization (ISH), using our mouse cDNA, was used to determine the spatial and temporal expression of NL-1 during mouse development, as done previously for PEX (Ruchon et al., 1998)). Serial sections of whole foetal (12, 15 and 19 dpc) and adult mice (1, 3 and 6 days old) were hybridized with an [<sup>35</sup>S]-labeled RNA probe. Figure 7 shows a section of mouse testis which was the only tissue identified to express NL-1 by this technique. Cells of seminiferous tubules are specifically labeled  
10 but spermatids located near the center of the tubule showed strongest labeling. These cells are in the last stage of maturation into spermatozooids. The presence of NL-1 in testis has now been confirmed by Northern analysis of mouse tissues (see Fig. 10). Other tissues express NL-1, when analyzed by RT-PCT, which is a more sensitive assay (not shown).

15 A similar approach was used to determine the localization of NL-3 using the mouse EST obtained from ATCC. Figure 8 shows sections of whole mouse at 17 days of embryonic development and 4 days post-natal. Several tissues are expressing this putative peptidase including brain, where it is associated with neurons (Figure 9), spinal chord, liver, spleen and bones. Labeling was stronger in bones from *Hyp* mouse,  
20 an animal model for hypophosphatemic rickets (Figure 8). In bones, NL-3 was found to be expressed by osteoblasts (not shown).

Northern blotting experiments were performed on several tissues with NL-2 and NL-3 probes. A Human Multiple Tissues Northern Blot (Clontech) was hybridized with specific probes. A single RNA band of approximately 4.0 kb was revealed by the probe  
25 for NL-2. Expression of NL-2 is restricted to brain and spinal cord (not shown). However, RT-PCR has shown the presence of this enzyme in testis (not shown).

A single RNA band of approximately 3.0 kb was detected with the specific probe for NL-3 (not shown). NL-3 expression was observed mainly in ovary, spinal cord and adrenal gland.

### 30 Chromosomal localisation of the human gene for NL-2 and NL-3

As a mean to get clues on the function of the new metallopeptidases in vertebrates, we have localized the new cDNAs on human chromosomes, in order to look for a possible link between the gene locus and mapped genetic diseases in humans. To do so, we have mapped the NL-2 and NL-3 genes by high-resolution  
35 fluorescence *in situ* hybridization (FISH). NL-2 was localized to chromosome band 1p36. Consistent with the cellular distribution of NL-2 in humans, genetic diseases of the CNS such as dyslexia, neural tube defect, neuroblastoma, neuronal type of Charcot-Marie-Tooth disease have all been mapped in this region and represent potential targets for a role of NL-2 in humans. NL-3 was localized to chromosome band

2q37. Consistent with a role of NL-3 in bones, a form of Albright hereditary osteodystrophy was mapped to the same chromosomal locus (Phelan et al., 1995).

In view of the foregoing, NL-2 and NL-3 are metallopeptidases that are assumed to be immediately useful as markers for a disease or disorder associated with human chromosomal locus 1p36 and 2q37, respectively. Their localization on a chromosome band associated with known diseases suggests that they may be expressed or co-expressed with one or more genes, as a cause or a consequence of disease development. It is possible that these enzymes are up or down regulated, alone or along with other genes involved in a disease. Therefore, antibodies or other ligands specific to NL-2 or NL-3 may be used for a diagnostic purpose, as well as primers or probes in diagnostic assays using nucleic acid hybridization or amplification techniques. Otherwise, primers or probes directed against the nucleic acids of NL-2 and NL-3 would be useful to map the mutations of a gene located in close proximity and involved in the disease. Therefore, no matter which exact function NL-2 and NL-3 gene products have, their chromosomal localization provides one diagnostic utility. This localization as well as the tissular distribution provide information as to the disease and tissue to be investigated to elucidate the exact function of these enzymes.

NL-1 resembles NL-2, sharing with the latter about 80% homology in the amino sequence and sharing structural characteristics such as the furin recognition sequence located at the proximal end of the ectodomain. NL-2 might be the human homologue of mouse NL-1. If such was the case, these two proteins would have a substantial degree of divergence and, maybe, different profiles of activity varying from one species to another.

Chromosomal localization of NL-1 was determined in mouse genome by Single Strand Conformational Polymorphism (SSCP) in collaboration with The Jackson Laboratory Backcross DNA Panel Mapping Resource. NL-1 was localized to the distal region of mouse chromosome 4 which corresponds to human chromosome region 1p36 where is located NL-2 gene. This reinforces our hypothesis that NL-1 and NL-2 are species variants.

#### Production of antibodies against NLs

Antisera collected from injected animals were first tested by immunoblotting on GST-antigen fusion proteins produced in *E. coli*. Antiserum from one rabbit recognized the NL-1-related polypeptide and antisera from one mouse and one rabbit reacted with the NL-3-related polypeptide (results not shown). The anti NL-1 antiserum and the mouse anti NL-3 antiserum, which appeared more specific than the rabbit antiserum, were next tested by immunoblotting on extracts of proteins and culture media from cells expressing NL-1 or NL-3 (see below).

#### Expression of NL-1 in CHO cells

The cDNA encoding the full-length NL-1 protein was cloned in the mammalian

expression vector pcDNA3-RSV and transfected in CHO cells. Stable cell lines were established by selection with the drug G418 and tested by immunoblotting for the presence of NL-1.

Small amounts of NL-1 were found in the extracts of transfected CHO cells (results not shown). This intracellular species was sensitive to endo H digestion, indicating that the sugar moiety was not mature and suggesting ER localization (results not shown). The culture medium of transfected CHO cells showed the presence of soluble NL-1 (Figure 10). This extracellular species was resistant to endo H suggesting true transport through the late secretory pathway. The cDNA sequence of NL-1 predicts a type II transmembrane protein. The mechanism by which NL-1 is transformed into a soluble protein is not known presently. However, examination of the amino acid sequence revealed the presence of a putative furin cleavage site from residue 58 to 65 (Figure 3). A similar site is present in NL-2 sequence.

The soluble form of NL-1 was assayed for activity using [<sup>3</sup>H]-Tyr-(D)Ala<sub>2</sub>-Leu-enkephalin and bradykinin as substrates. Figure 11 shows that NL-1 can degrade the enkephalin substrate ( $K_m = 18 \pm 10 \mu M$ ) and that this activity can be inhibited by phosphoramidon ( $IC_{50} = 0.9 \pm 0.3 nM$ ) and thiorphan ( $K_m = 47 \pm 12 nM$ ), a general inhibitor of enzymes of the NEP family. Bradykinin is also a substrate for NL-1 (not shown).

#### Use of NL-1 amino-terminal domain to promote secretion

The observation that NL-1 ectodomain was secreted, possibly through cleavage of the transmembrane segment by furin, raised the possibility to promote secretion of exogenous proteins that could be spliced to NL-1 amino-terminal domain (from initiator methionine to the furin site). To test this hypothesis, the ectodomain of NL-3 (from the third cysteine to the end) was spliced to NL-1 amino-terminal domain using a PCR strategy and the recombinant DNA cloned in expression vector pRcCMV. The fusion protein was expressed by transfection of the vector in COS-1 and HEK 293 cells. The culture media of transfected cells was analyzed by immunoblotting using the mouse antiserum against NL-3. Figure 12 shows the presence of NL-3 in the spent culture media of both COS-1 and HEK 293 cells. This result shows that NL-1 amino-terminal domain can be used to promote secretion of exogenous proteins.

The soluble form of NL-3 was assayed for activity using [<sup>3</sup>H]-Tyr-(D)Ala<sub>2</sub>-Leu-enkephalin as substrate. No activity was found.

The previous experiment showed that it was possible to use the amino-terminal domain of NL-1 to promote secretion of an otherwise membrane attached protein ectodomain. To verify whether the same strategy could be used to promote secretion of small peptides, a PCR strategy was used to splice human  $\beta$ -endorphin to the amino-terminal domain of NL-1 and the recombinant DNA was cloned in vector pRcCMV. The fusion protein was expressed by transfection of the vector in COS-1 and HEK 293 cells. The culture media of transfected cells was collected 48h after transfection and

the peptides purified as described previously (Noël et al., 1989). The presence of  $\beta$ -endorphin in the extracts was detected by radioimmunoassay. The results showed that both COS-1 and HEK 293 cells produced approximately 100 pg of  $\beta$ -endorphin per ml of culture medium. Therefore, the N-terminus of LN-1 and NL-2 which ends with a furin-recognition site will be useful to produce the soluble form of a protein of interest.

## SECTION 2)

### MATERIALS AND METHODS

#### 10 DNA manipulations

All DNA manipulations, phage library screening, and plasmid preparations were performed according to standard protocols (Ausubel 1988; Sambrook 1989). Site-directed mutagenesis was performed using a PCR-based strategy as described previously (Le Moual 1994).

15

#### **mRNA purification and RT-PCR protocol for identification of new members of the neprilysin family**

mRNAs were prepared from mouse testis using Quick Prep Micro mRNA purification kit (Pharmacia Biotech). First strand cDNA was synthesized from 1  $\mu$ g of mRNA using the First-Strand cDNA synthesis kit (Pharmacia Biotech).

20

Two sense primers, oligonucleotide 3817 (5'-TGGATGGAT/CGA/CIGG/AIACIA/CA-3') and oligonucleotide 3719 (5'-AGTIGTITTT/CCCIGCIGGIA/GT/AIC/TTG/CCA-3') corresponding respectively to amino acid residues 459 to 465 and 552 to 560 of NEP sequence, and one antisense primer, oligonucleotide 3720 (5'-AIICCIACCIA/TC/TA/GTCIGCIG/AC/TA/GTTT/CTC-3') corresponding to amino acid residues 646 to 654 (see Fig. 1 and 2), were synthesized. PCR was performed with 5  $\mu$ l of cDNA template and 1  $\mu$ l of Taq DNA polymerase in a final volume of 100  $\mu$ l, containing 1 mM  $MgCl_2$ , 2  $\mu$ M of each oligonucleotide 3817 and 3720, 200  $\mu$ M of each dNTP and 5% DMSO. Cycling profiles included an initial denaturation step of 5 min at 94°C, 30 cycles of 1 min at 94°C, 1 min at 40°C and 1.5 min at 72°C, and a final extension step at 72°C for 10 min. One half of the amplified DNA was fractionated on a 2% agarose gel and fragments ranging in size between 500-700 bp were purified and resuspended in a final volume of 50  $\mu$ l. A second round of PCR was done with primers 3719 and 3720, using as template either 10  $\mu$ l of the first PCR reaction or 5  $\mu$ l of the purified fragments, and the new PCR products were ligated in pCR2.1 vector (Invitrogen). Several identical clones corresponded to a potential new member of the NEP family. We called this member NL1 for NEP-like 1.

35

#### **Cloning of full-length NL1 cDNA**

The cloned NL1 PCR fragment was used as probe to screen a mouse testis  $\lambda$  Uni-ZAP<sup>TM</sup>XR cDNA library (Stratagene). Twelve out of a hundred positive phages were plaque purified and subcloned into pBS SK vector (Stratagene). As the longest clone analyzed presented an incomplete ORF (pBS-NL1A), 5'RACE with primers located in vector (5'-TAGTGGATCCCCCGGGCTGCAG-3', sense primer) and NL1 (5'-ACCAAACCTTTCCTGTAGCTCC-3', antisense primer, nt 1303 to 1324 of NL1; was subsequently performed on the DNA of the remaining semi-purified positive clones. Amplification was performed with 1  $\mu$ l of Vent polymerase in a final volume of 100  $\mu$ l containing 50 ng of DNA, 4 mM of MgSO<sub>4</sub>, 1  $\mu$ M of each oligonucleotide, 200  $\mu$ M of each dNTP and 10% DMSO. Cycling parameters included an initial denaturation step of 1 min at 94°C, 25 cycles of 30 sec at 94°C, 30 sec at 60°C and 1 min at 72°C, and an incubation of 10 min at 72°C. A PCR fragment of the expected length was subcloned into pCR2.1 vector (clone pCR-NL1A), but sequencing revealed no initiator ATG codon. A nested 5'RACE was then performed on mouse testis cDNA using the Marathon Ready cDNA kit (Clontech) with sense oligonucleotides AP1 and AP2 (from the kit) and NL1 antisense oligonucleotides 5'-CCTGAGGGCTCGTTTTACAACCGTCCT-3' (nt 503 to 529 of NL1) and 5'-CTCATCCCAGGAGAAGTGTAGCAGGCT-3' (nt 475 to 502 of NL1) as recommended by the supplier. The resulting fragment was cloned into pCR2.1 vector (pCR-NL1B). Since only ten bp were missing for the initiator ATG codon, we reconstructed the 5' end of the cDNA by PCR-amplifying clone pCR-NL1A with sense primer 5'-CCACCATGGTGGAGAGAGCAGGCTGGTGTCTCGGAAGAAG-3' (nt 332 to 364 of NL1; the 10 missing nucleotides are underlined) and antisense primer 5'-ACCAAACCTTTCCTGTAGCTCC-3' (nt 1303 to 1324 of NL1) using Vent polymerase as described above. The DNA fragment was then inserted into pCR2.1 (clone pCR-NL1C). The entire ORF was reconstituted following digestion of pBS-NL1A and pCR-NL1C with *Eco*RI and *Pfi*MI. The 5' end of NL1 cDNA was excised from pCR-NL1C and ligated into pBS-NL1A at the corresponding sites, resulting in plasmid pBS-NL1B.

For expression studies, a *Bam*HI/*Ap*al fragment generated out of pBS-NL1B, corresponding to the full length cDNA of NL1, was inserted into pCDNA3/RSV [18] vector.

#### Production of polyclonal antibodies

A plasmid for the production in *Escherichia coli* of a GST fusion protein with NL1 was constructed using pGEX-4T-3 expression vector (Pharmacia Biotechnologies). A 255 bp fragment from NL1 was amplified by PCR with Vent polymerase using sense primer 5'-GCTACGGGATCCGTGGCCACTATGCTTAGGAA-3' (nt 1139 to 1158) and antisense primer 5'-CGATTGCTCGAGTGGGAACAGCTCGACTTCCA-3' (nt 1377 to 1396). Both pGEX-4T-3 and the PCR product were digested with *Bam*HI and *Xho*I

and ligated. The recombinant protein was produced and purified according to the supplier's instructions. Five weeks old female balb/c mice were immunized at monthly intervals for 3 months with 20 µg of the recombinant NL1 fragment in Freund's adjuvant and antisera were subsequently collected.

5

#### Cell culture and transfection

Human Embryonic Kidney (HEK 293) cells were maintained in DMEM medium containing 10% fetal bovine serum (FBS), and supplemented with penicillin at 60 µg/ml, streptomycin at 100 µg/ml and fungizone at 0,25 µg/ml. Transfections of cells with appropriate plasmids were performed by the calcium/phosphate-DNA co-precipitation method (Chang 1987). To establish permanent cell lines, G418 selection was initiated 48 h after the transfections at 400 µg/ml for 12 days and gradually decreased at 100 µg/ml.

10

LLC-PK<sub>1</sub> cells transfected with pRcCMV-sNEP were maintained as described previously (Lanctôt 1995).

#### Immunoblot analysis

For immunoblot analysis, cells were incubated for 16 h in synthetic DMEM medium containing 2mM sodium butyrate. Cellular proteins were solubilized as previously described (Dion 1995). Secreted proteins recovered in culture media were concentrated approximately 10 fold by ultrafiltration. Immunoblot analysis were performed using the NEN Renaissance kit with the polyclonal antibody specific to NL1 or the α1-antitrypsin inhibitor antibody (Calbiochem; LaJolla, CA) followed by the appropriate horseradish peroxidase-conjugated IgG (Vector Laboratories).

20

For the glycosylation studies, proteins were incubated with endoglycosidase H (endoH) or peptide:N-glycosidase (PNGaseF) as suggested by the distributor (NEB).

#### Enzymatic activity assays

NL1 activity was monitored and compared to sNEP activity using (Tyrosyl-[3,5-<sup>3</sup>H])(D-Ala<sub>2</sub>)-Leu<sub>5</sub>-enkephalin (50 Ci/mmol) (Research Products International Inc.), as already described (Dion 1995; Devault 1988). *K<sub>m</sub>* values were determined by the isotope-dilution method. The inhibitory effects of phosphoramidon and thiorphan were also assessed as previously described (Dion 1995).

30

#### HPLC analysis of the hydrolysis of Leu-enkephalin

Five µg of Leu<sub>5</sub>-enkephalin were incubated at 37°C for one hour in 50mM MES, pH 6.5, with concentrated culture medium of HEK 293 cells expressing NL1 (~300 µg of total proteins) or LLC-PK<sub>1</sub> cells expressing sNEP (~30 µg of total proteins), in absence or presence of 0.1 mM phosphoramidon. Hydrolysis products were separated by

35

091339-03101



reversed-phase HPLC as described previously [23]. Tyr-Gly-Gly and Phe-Leu were both identified by elution profiles of synthetic marker peptides.

### Northern blot analysis

5       A mouse multiple tissue poly(A)<sup>+</sup> mRNA blot (Clontech) was hybridized with a [<sup>32</sup>P]dCTP random primer labelled probe in ExpressHyb solution (Clontech). The blot was washed according to the manufacturer's recommendations and exposed to Fuji RX film for 7 days at -80°C with intensifying screens.

### 10      RT-PCR screening of mouse tissues

First strand cDNA synthesis was performed with 1 µg of total RNA from mouse tissues and oligo(dT) as primer, using Gene Amp RNA PCR Core Kit (Perkin Elmer). For the PCR reactions, primers 5'-TGGCGAGAGTGTGTCAGCTATGTC-3' and 5'-CTTCCAAAATGTAGTCAGGGTAGCCAATC-3' were used with Taq polymerase. One  
15      tenth of the PCR products were visualized on a 4% agarose gel.

### In situ hybridization

To construct a plasmid for the synthesis of cRNA probes for ISH, pCR-NL1A was used as template to amplify a 452 bp fragment by PCR with sense primer 5'-  
20      GGAGCCATAGTGACTCTGGGTGTC-3' (nt 416 to 439) and antisense primer 5'-GACGCTCAGCAGGGGCTCAGAGTC-3' (nt 842 to 865). The amplification product was inserted into pCRII vector (Invitrogen). Synthesis of riboprobes and protocols for ISH were as described previously (Ruchon 1998).

## RESULTS

25

### Cloning and sequence analysis of mouse NL1 cDNA

In order to isolate cDNAs for new members of the NEP family, we developed an RT-PCR strategy based on fact that NEP, ECE-1 and PHEX share regions of significant sequence identity. Following RT-PCR on testis mRNAs with nested primers,  
30      a DNA fragment of approximately 300 bp was amplified. This DNA fragment was cloned and the plasmids from 24 independent colonies were sequenced: 3 clones had no insert, 4 clones had DNA fragments not related to the NEP family, 7 clones had sequences corresponding to mouse NEP and 3 clones had sequences corresponding to mouse PHEX, showing that our approach efficiently allowed the identification of  
35      members of the family. Moreover, 7 identical clones had a new cDNA presenting sequence similarities to members of the NEP family. The full-length cDNA was subsequently obtained by screening a mouse testis λ cDNA library followed by 5'RACE, as described under *Materials and Methods*. Its nucleotide and deduced amino acid sequences confirm that we cloned a novel NEP-like protein, referred to

thereafter as NL1.

NL1 cDNA spans 2925 nt, including a 5'-untranslated region of 331 nt, an open reading frame of 2295 nt from nt 332 to nt 2626, and a 3'-untranslated region of 299 nt. The sequence surrounding the proposed initiator ATG conforms to the Kozak consensus (Kozak 1986). The deduced amino acid sequence of NL1 reveals a putative type II transmembrane protein of 765 amino acid residues encompassing a short N-terminal cytoplasmic tail, a unique putative transmembrane domain, and a large C-terminal extracellular domain. The ectodomain contains nine potential N-glycosylation sites (Asn-X-Ser/Thr) and ten cysteine residues corresponding to those conserved among all the members of the family, which are presumably involved in proper folding and in maintenance of the protein in an active conformation. All amino acid residues known to be part of the active site of NEP are present in NL1. The predicted protein presents greater similarities to NEP than to any other member of the family.

Although NL1 shares numerous features with proteins of the neprilysin family, a notable aspect distinguishes it from the others : the first conserved cysteine residue of the ectodomain is more distant (34 amino acid residues) from the predicted transmembrane domain in NL1 than it is in NEP (9 residues) or any other members of the family. Moreover, we noticed a putative furin cleavage site (-Arg<sub>58</sub>-Thr-Val-Val-Lys-Arg<sub>63</sub>-) between the end of the transmembrane domain and the first cysteine. This observation suggests that NL1 could exist as a secreted rather than a membrane-bound protein.

#### NL1 expression in HEK 293 cells

HEK 293 cells were transfected with pCDNA3/RSV expression vector containing NL1 cDNA, and a permanent cell line was established as described under *Materials and Methods* (HEK/NL1 cells). Immunoblotting with a polyclonal antibody showed that after 16h of culture, most NL1 was present in the culture medium with small amounts of the enzyme in the cell extract. Secreted and cell-associated NL1 had apparent molecular masses of approximately 125 and 110 kDa, respectively. To characterize the glycosylation state of NL1, we next submitted the recombinant protein to deglycosylation by peptide : N-glycosidase F (PNGase F) and endoglycosidase H (endo H). PNGase F removes high mannose as well as most complex N-linked oligosaccharides added in the Golgi complex. In contrast, endo H removes N-linked oligosaccharide side chains of the high mannose type found on proteins in the RER but which have not yet transited through the Golgi complex; thus, resistance to endo H can be used as an indication that the protein has traveled through the Golgi complex. PNGase F treatment showed that the cell-associated and secreted NL1 were N-glycosylated as their electrophoretic mobility increased following digestion. However, the secreted NL1 migrated as a doublet after PNGase F treatment, with one

band co-migrating with cell-associated form and the second having a slower rate of migration. Since untreated and endo H-digested secreted NL1 are seen as single bands by SDS-PAGE, our observation suggests that a proportion of secreted NL1 undergoes further post-RER postranslational modification that renders some of the N-linked oligosaccharides resistant to PNGase F digestion.

In contrast to secreted NL1, NL1 from cell extract was sensitive to endo H treatment. This result shows differences in the glycosylation state of the two species and suggests that the cell-associated form observed in transfected cells is an intracellular species that has not traveled through the Golgi complex.

### Processing of NL1 by a subtilisin-like convertase

To determine whether a member of the mammalian subtilisine-like convertase family is responsible for NL1 presence in the culture medium of transfected cells, we co-transfected transiently HEK 293 cells with a constant amount of plasmid pCDNA3/RSV/NL1 and increasing amounts of plasmid pCDNA3/CMV/PDX (Benjannet 1997). This latter vector promotes the expression of the  $\alpha$ 1-antitrypsin Portland variant,  $\alpha$ 1-PDX, a known inhibitor of subtilisin-like convertases (Anderson 1993). Immunoblot analysis of the culture media of cells expressing both NL1 and  $\alpha$ 1-PDX indicated that NL1 secretion was strongly inhibited by the presence of  $\alpha$ 1-PDX: a relation was observed between the amounts of  $\alpha$ 1-PDX and the level of inhibition of NL1 secretion.

To confirm that proteolysis by the subtilisin-like convertase occurred at the putative furin cleavage site identified in NL1 ectodomain (-Arg<sub>58</sub>-Thr-Val-Val-Lys-Arg<sub>63</sub>-), the amino acid residues Asn<sub>62</sub>-Gly<sub>63</sub> were substituted for Lys<sub>62</sub>-Arg<sub>63</sub> by site-directed mutagenesis in vector pCDNA3/RSV/NL1 and the mutated vector used to establish HEK 293 cells expressing the mutant protein (HEK/NL1mut cells). Immunoblot analysis of the culture media of HEK/NL1mut cells showed that the mutation totally abolished secretion of NL1. Furthermore, an additional form of NL1 with a molecular mass of 127 kDa was detected in the extract of these cells. This new species was resistant to endo H digestion and was found associated with membranes when HEK/NL1mut cells were fractionated according to Chidiac *et al.* 1996 (result not shown).

### NL1 enzymatic activity

Culture media from HEK 293 and HEK/NL1 cells were tested for enzymatic activity using as substrate (Tyrosyl-[3,5-<sup>3</sup>H])(D-Ala<sub>2</sub>)-Leu<sub>5</sub>-enkephalin, a known NEP substrate. Activity was detected in the culture medium of HEK/NL1 cells but not in that of HEK 293 cells. This activity increased linearly with the amounts of NL1 and with the incubation period, indicating that degradation of the substrate was due to NL1 enzymatic activity.

We next characterized NL1 enzymatic parameters using the same substrate

and compared them to those of an engineered soluble form of NEP (sNEP) (Lemay 1989). NL1 affinity for D-Ala<sub>2</sub>-Leu<sub>5</sub>-enkephalin was slightly higher than that of sNEP as shown by their  $K_m$  values of 18  $\mu$ M and 73  $\mu$ M, respectively. Inhibition assays showed that phosphoramidon had similar effects on NL1 and sNEP activity, with  $IC_{50}$  values of 0.9 nM and 0.5 nM respectively, and that thiorphan, a specific inhibitor of NEP, inhibited NL1 with an  $IC_{50}$  of 47 nM, as compared with an  $IC_{50}$  of 8 nM for NEP.

Very low levels of phosphoramidon-sensitive activity was detected in extracts of HEK/NL1 cells (data not shown) consistent with the small amounts of NL1 observed by immunoblotting.

To determine whether NL1 had cleavage site specificity similar to NEP, we incubated Leu<sub>5</sub>-enkephalin in the presence of NL1 recovered from the medium of HEK/NL1 cells or in the presence of sNEP, and analyzed the degradation products by RP-HPLC. Peaks co-migrating with standard Tyr-Gly-Gly and Phe-Leu peptides were observed in both RP-HPLC profiles, indicating that both enzymes cleaved the substrate at the Gly<sub>3</sub>-Phe<sub>4</sub> peptide bond. This enkephalin-degrading activity was completely inhibited by phosphoramidon (1  $\mu$ M).

#### Tissue and cellular distribution of NL1 mRNA

Tissue distribution of NL1 mRNA was determined by Northern blot analysis with a specific probe corresponding to the 5' end of the coding region of NL1 cDNA. A single transcript of 3.4 kb was detected exclusively in testis among all the mouse tissues tested. Mouse tissues were also screened by RT-PCR. Using this more sensitive technique, expression of NL1 was observed in several other tissues including heart, brain, spleen, lungs, liver and kidney. Consistent with the Northern blot results, RT-PCR analysis, although not strictly quantitative, detected more NL1 mRNA in testis than in other tissues.

To gain more insight into NL1 mRNA distribution, we examined by ISH cryostat sagittal sections from a 4-day newborn mouse, as well as sections from a 16-day old animal (p16) and adult tissues (heart, brain, spleen, lungs, liver, kidney and testis). The presence of NL1 mRNA was detected only in adult testis. Only the germinal cells in the luminal face of the seminiferous tubules were labeled. These cells were identified as round and elongated spermatids in all spermiogenesis maturational stages. Neither spermatozoa nor spermatocytes, spermatogonies or Sertoli cells were labeled. Interstitial cells were also negative. Controls were performed with sense riboprobes, which produced only nonspecific background (data not shown). The 4-day old mouse sagittal sections and all other tissues tested were negative.

#### DISCUSSION

The great interest in members of the Neprilysin family as putative therapeutic

targets, and the recent discovery of new members of this important family of peptidases led us to investigate whether additional members of the family remained to be identified. Using a PCR-based strategy, we cloned, from mouse testis, a partial cDNA encoding a new NEP-like enzyme that we called NL1. Analysis of the amino acid sequence encoded by the full-length NL1 cDNA revealed that this member of the family resembles NEP the most: 55% identity and 74% similarity. Recently, the primary structure of a new zinc metallopeptidase from total mouse embryo was reported (Ikeda 1999). This enzyme, called SEP, is found either as a soluble or a cell-associated form due to alternative splicing. NL1 shows only 3 amino acid differences with the soluble form of SEP indicating that secreted SEP and NL1 are the same enzyme. Our cloning strategy did not allow characterization of the cell-associated form of NL1 which is a minor species in mouse testis (Ikeda 1999).

The amino acid sequence of NL1 predicts a topology of a type II integral membrane glycoprotein that is similar to the other members of the family. Treatment of the recombinant protein with PNGase F showed that indeed NL1 possesses N-linked carbohydrate side chains. However, it is not possible to determine precisely whether all nine putative N-glycosylation sites are used, but the 30 kDa decrease in molecular mass upon PNGase F treatment suggests that most are glycosylated. It has already been shown that all asparagine residues in a Asn-X-Ser/Thr consensus are glycosylated in rabbit NEP expressed in COS-1 cells and that sugar moieties increase the stability and enzymatic activity of the protein and facilitate its intracellular transport (Lafrance 1994). Three of NEP glycosylated Asn residues (Asn 145, Asn 285 and Asn 628) are conserved in NL1 (Asn 163, Asn 303 and Asn 643). Amongst these residues, Asn 145 and Asn 628 have been reported to influence NEP enzymatic activity (Lafrance 1994). In the same work, it has also been shown that the effect of sugar addition on folding and intracellular transport of NEP is a cumulative effect of all glycosylation sites rather than a contribution of any particular one. Glycosylation of NL1 may share similarities with that of NEP since we found their primary structures and enzymatic activities to be very similar.

Surprisingly, expression of the cDNA by transfection of HEK 293 cells showed that most of the enzyme was secreted in the culture medium. The small amount of NL1 associated with the cells was endo H-sensitive, suggesting that the cell-associated enzyme is a species that has not yet left the RER. The presence of a furin cleavage site in NL1 sequence between the predicted transmembrane domain and the first conserved cysteine residue of the ectodomain led us to believe that a member of the mammalian subtilisin-like family of convertases was responsible for the presence of NL1 in the culture medium. These enzymes are involved in processing a variety of precursor proteins such as growth factors and hormones, receptors, plasma proteins, matrix metalloproteinases, metalloproteases-desintegrins and viral envelope

glycoproteins [for a review see: (Nakayama 1997). Site-directed mutagenesis of the furin cleavage site (-Arg<sub>58</sub>-Thr-Val-Val-Lys-Arg<sub>63</sub>-) and expression of  $\alpha$ 1-PDX, a potent inhibitor of mammalian subtilisin-like convertases (Anderson 1993), confirmed that a member of this family of endoproteases was involved in NL1 secretion presumably by cleaving in carboxy-terminus of Arg<sub>63</sub>. There are only a few examples of proteins which are processed from a membrane-bound precursor to a secreted form following cleavage by subtilisin-like convertases; these include meprin and collagen XVII (Milhiet 1995; Schacke 1998). Three members of the subtilisin-like family of convertases, namely furin, PC4 and PC7, are known to be expressed in germ cells (Nakayama 1992; Torri 1993; Seidah 1992, 1996). Whether one of these convertases generates secreted NL1 from its membrane form is under current investigation. In any case, NL1 is the only known member of the neprilysin family that is secreted. This unique feature suggests that NL1 plays its physiological role in a context different from that of the membrane-bound peptidases, thereby diversifying the role of the peptidases of the neprilysin family. It is of interest that circulating forms of NEP in blood and urine have been described, but they have generally been related to pathological or stressful conditions (Almenoff 1984; Deschodt-Lanckmann 1989; Johnson 1985; Soleilhac 1996; Aviv 1995).

We have observed in cells expressing NL1 mutated at the furin cleavage site the appearance of a species resistant to digestion by endo H. This mutated protein was associated with cellular membranes. Taken together, these results indicate that NL1 is first synthesized and inserted in the RER membrane as a type II transmembrane protein. During intracellular transport, NL1 is converted to a soluble form by the action of a member of the mammalian subtilisin-like convertases. The identity of the cellular compartment where this process occurs is not known. However, mammalian subtilisin-like convertases are usually active in post-Golgi compartments of the secretory pathway suggesting that processing of NL1 from the membrane bound form to the soluble form is a post-Golgi event.

Despite almost total abrogation of NL1 secretion, we observed only a slight accumulation of endo H-resistant NL1 in cells either co-expressing  $\alpha$ 1-PDX and NL1 (result not shown) or expressing mutated NL1. This observation suggests that unprocessed NL1 is rapidly degraded. A similar behavior was reported for the Notch1 receptor expressed in the furin-deficient cell line LoVo (Logeat 1998). The mechanism(s) by which these unprocessed proteins are degraded is still unknown. It is interesting to point out that the spliceoform of SEP that has lost a 23 amino acid peptide, including the furin cleavage site, generates a cell-associated endo H-sensitive molecule (Ikeda 1999).

The most important observation regarding the NL1 primary structure is the conservation of residues which in NEP are essential for catalysis and binding of

substrates or inhibitors. This finding suggests that NL1 could effectively act as an endopeptidase with a catalytic mechanism similar to that of NEP. This hypothesis was supported by the demonstration that D-Ala<sub>2</sub>-Leu<sub>5</sub>-enkephalin, a peptide substrate often used to monitor NEP activity, was also an excellent NL1 substrate. The affinity of NL1 for D-Ala<sub>2</sub>-Leu<sub>5</sub>-enkephalin was even higher than that of NEP, as reflected by a  $K_m$  value 4- to 5-fold lower. Furthermore, two well known NEP inhibitors, phosphoramidon and thiorphan, also abolished NL1 activity. Phosphoramidon, which inhibits NEP as well as ECE-1 activity, albeit to a lesser extent (Turner 1996), had very similar effects on NL1 and NEP, with an IC<sub>50</sub> value for NL1 varying not more than two-fold from the value determined for NEP. Thiorphan, considered to be a more specific inhibitor of NEP, also inhibited NL1 activity, with an IC<sub>50</sub> six-fold greater than that for NEP. These results suggest that the active sites of NL1 and NEP are similar. This hypothesis is supported by the observation that secreted SEP degraded a set of peptides known to be NEP substrates, including substance P, bradykinin and atrial natriuretic peptide (Ikeda 1999). Taken together, these results illustrate the importance of identifying and characterizing other member of the family for the design of highly specific inhibitors.

In agreement with the enzymatic parameters demonstrating that NL1 and NEP have similar catalytic sites, we have observed that both enzymes cleaved Leu<sub>5</sub>-enkephalin at the same peptide bond. This result suggests that NL1 hydrolyzes peptide bonds on the amino side of hydrophobic amino acid residues as does NEP (Turner 1985). However, several other peptides will have to be tested to confirm this specificity and to determine whether NL1 has dipeptidyl carboxypeptidase activity as was shown for NEP (Malfroy 1982; Bateman 1989; Beaumont 1991) and more recently for ECE-1 (Johnson 1999).

RT-PCR experiments with specific primers for the soluble and cell-associated forms of SEP showed a wide tissue distribution of the enzyme with the soluble form of SEP being predominant in testis and the cell-associated form in other tissues (Ikeda 1999). Our RT-PCR results confirmed the wide tissue distribution of NL1. However, Northern blotting and *in situ* hybridization experiments indicated that expression of NL1 is predominant in germ cells of mature testis. Interestingly, proenkephalin mRNA has been shown to be expressed in germ cells and somatic cells of the testis (Torii 1993, Seidah 1992; Kew 1989; Mehta 1994; Kilpatrick 1986, 1987). Specific functions for testicular enkephalin peptides have not yet been defined, but it is believed that they could act as intratesticular paracrine/autocrine factors. In addition to their putative role as mediators of testicular cell communication, it has also been demonstrated that proenkephalin products synthesized by spermatogenic cells during spermatogenesis are stored in the acrosome of human, hamster, rat and sheep spermatozoa and are release from sperm following acrosomal reaction (Kew 1990). It has thus been proposed that proenkephalin products may act as sperm acrosomal factors during the

fertilization process as well as intratesticular regulators secreted by spermatogenic cells. Since Leu<sub>5</sub>-enkephalin was found to be a good substrate for NL1, opioid peptides originating from proenkephalin could serve as physiological substrate for this new enzyme. In this way, NL1 would serve to regulate the activity of these bioactive peptides.

Testis is the only tissue where the soluble form of SEP is predominant (Ikeda, 1999), suggesting a testis-specific alternative splicing. Expression of testis-specific molecular species of peptidases or prohormones, arising through diverse mechanisms, has been documented in the past (Howard 1990; Jeannotte 1987). However, the physiological significance of these testis-specific species is not always clear. In the case of NL1 or SEP, it might allow local constitutive secretion by germinal cells of an otherwise cell-associated enzyme, to regulate spermatogenesis much like several other proteolytic enzymes of the seminiferous tubules (Monsees 1998). Alternatively, it might allow accumulation in acrosome with proenkephalin peptides and release upon acrosomal reaction. More exhaustive studies concerning NL1 localization and physiological substrate identification will be needed to understand its role in the testis and possibly in the fertilization process.

#### Cloning of other members of the family

To find other members of the NEP-like family, we will use the same RT-PCR strategy to amplify mRNA isolated from tissues known to be regulated by peptidergic systems (brain, thymus, kidney, heart, lung, ovary, pancreas, bone, bone marrow and lymphoid cells). In fact, many of these tissues are known to express at least one member of the family and/or to control a peptidergic pathway on which peptidase inhibitors have major effects. Amplified fragments will be cloned and the resulting clones will be sequenced and compared to the sequence of known peptidases, as described above. Pairs of degenerate primers in other highly conserved regions will also be designed to increase the possibility of cloning other relevant peptidases.

#### **DISCUSSION**

As discussed above, peptidases of the NEP family known to date have often been found to play important physiological roles. This is certainly true for NEP itself, ECEs and PEX, (see review above). For this reason, some of these enzymes (as it was the case for NEP and ECE in the past) might be interesting targets for the design of inhibitors that in turn could be used as therapeutic agents in various pathological conditions. However, it is of some concern that inhibitors designed for one enzyme may also inhibit to some extent other members of the family. This lack of specificity for an inhibitor used as a therapeutic agent in the long term treatments such as those used as antihypertensive agents for instance, may cause unforeseen problems due to unwanted side effects. The objectives of the present work was to develop a strategy



to clone new members of the NEP family of peptidases. The results presented in this report clearly show that our strategy can be successful. We have determined the complete or partial nucleotide sequence of three cDNAs encoding putative enzymes of the NEP family.

5        These cDNA sequences are valuable tools and may be used to:

Produce antibodies

As shown in the present work, knowledge of NL cDNA sequences can be used to raise specific antibodies. For example but not exclusively, regions of less homology between the peptidases (amino acid residues 50 to 450) can be used to synthesize peptides whose sequences are deduced from the translation of the cDNAs, and/or bacterially-expressed fragments of the cDNAs fused for example but not exclusively to GST may be purified and injected into rabbits or mice for polyclonal or monoclonal antibody production. These antibodies can be used to:

- 15        - identify by immunohistochemistry the peptidergic pathways in which the peptidases are functioning;
- study the physiopathology of NL-enzymes by immunoblotting or immunohistochemistry on samples of biological fluids or biopsies;
- set up high through put screening assays to identify NL-enzymes inhibitors. This can be done for example but not exclusively by using the antibodies to attach the NL-enzymes to a solid support;
- 20        - purify NL-enzymes with said antibodies by immunoprecipitation or affinity chromatography by identifying antibodies capable of selectively binding to the NL-enzymes in one set of conditions and releasing it in another set of conditions typically involving a large pH or salt concentration change without denaturing the NL-enzyme;
- 25        - identify antibodies that block NL-enzymes activities and use them as therapeutic agents. Blocking antibodies can be identified by adding antisera or ascite fluid to an *in vitro* enzymatic assay and looking for inhibition of NL-enzymes activities. Blocking antibodies could then be injected to normal or disease model animals to test for *in vivo* effects.

Derive specific RNA or DNA probes

As shown in the present work, knowledge of the nucleotide sequence of the members of the NEP-family allows nucleotide sequence comparisons and facilitate the design of specific RNA or DNA probes by methods such as but not exclusively molecular cloning, *in vitro* transcription, PCR or DNA synthesis. The probes thus obtained can be used to:

- 35        - derive specific probes or oligonucleotides for RNA and DNA analysis, such as Northern blot and *in situ* hybridization, chromosome mapping

or PCR testing. These probes could be used for genetic testing of normal or pathological samples of biological fluids or biopsies;

- make vectors for gene knock-out or knock-in in mice. The long range PCR technique and/or screening of a mouse genomic library with probes derived from the 5'-end of the cDNAs can be used to isolate large exon/intron regions. We will then substitute one or more of the cloned genomic DNA exons for the neomycin resistance expression cassette for producing homologous recombination and knock-out mice. Alternatively, cDNAs coding for NLs will be used to overexpressed each of these enzymes in transgenic mice. The cDNAs will be cloned downstream from a promoter sequence, and injected in fertilised mouse eggs. Depending on specific questions to be answered, the chosen promoter sequence will allow expression of the peptidases either in every tissues or in a cell- or tissue-specific manner. Injected eggs will be transferred into foster mothers and the resulting mice analysed for peptidase expression;
- replace defective NL genes in a gene therapy strategy. The NL full length cDNAs could be cloned under the control of a constitutive or inducible promoter having a narrow or wide range of tissue expression and introduced with appropriate vectors in subjects having defective genes;
- synthesise oligonucleotides that could be used to interfere with the expression of the NLs. For example but not exclusively, oligonucleotides with antisens or ribozyme activity could be developed. These oligonucleotides could be introduced in subjects as described above;
- isolate other members of the family. Screening cDNA and/or genomic libraries with these cDNA probes at low stringency may allow to clone new members of the NEP-like family. Alternatively, alignment of the sequences may allow one to design specific degenerate oligonucleotide primers for RT-PCR screening with mRNA from tissues such as but not exclusively, the hearth and the brain.

#### Production of recombinant NL-enzymes

As shown in the present work, recombinant active NL-enzymes can be obtained by expression of NL-cDNAs in mammalian cells. From past experience with neprilysin, another member of the family (Devault *et al.*, 1988; Fossiez *et al.*, 1992; Ellefsen *et al.*, submitted), expression can also be performed in other expression systems after cloning of NL-cDNAs in appropriate expression vectors. These expression systems may include but not exclusively the baculovirus/insect cells or larvae system and the *Pichia*

*pastoris*-based yeast system. Production of recombinant NL-enzymes includes the production of naturally occurring membrane bound or soluble forms of the proteins or genetically engineered soluble forms of the enzymes. The latter can be obtained by substituting the cytosolic and trans-membrane domain by a cleavable signal peptide such as that of proopiomelanocortin, but not exclusively, as done previously (Lemay *et al.*, 1989) or by transforming by genetic manipulations the non-cleavable signal peptide membrane anchor domain into a cleavable signal peptide, as done previously (Lemire *et al.*, 1997) or by fusion of the ectodomain of NL-enzymes to the amino-terminal domain (from the initiator methionine to amino acid residue 300) of naturally occurring soluble NLs such as, but not exclusively, NL-1 as done in this work.

These recombinant NLs could be used to:

- find a substrate. A substrate can be identified using one of the following.
- Screening of existing bioactive peptides. Peptides are incubated in the presence of NL-enzymes and subsequently analysed by HPLC for degradation. Degradation is observed by disappearance of the peak of substrate and the appearance of peaks of products;
- Screening phage libraries specifically designed for the purpose (phage display library). Each phage expresses at its surface, as part of its coat protein, a random peptide sequence preceded by a peptide sequence recognisable by an antibody or any other sequence-recognizing agent. This latter sequence serves to attach the phage to a solid support. Upon addition of the NL-enzyme the random sequences that are NL substrate are cleaved, releasing the phage. After several rounds of cleavage, the phage sequence is determined to identify the peptide segment recognized by the enzyme.
- Extract of the tissue where the enzyme is expressed is collected and prepared for chromatographic analysis (HPLC, capillary electrophoresis or any other high resolution separation system) by denaturing the extracted proteins with a solvent (acetonitrile or methanol). The extract is subjected to chromatographic separation. The same extract is incubated with the enzyme for a period sufficient to observe a difference between the 2 chromatograms. The regions with the identified changes are collected and subjected to mass spectrometric analysis to determine the peptide compositions.
- Small peptide libraries are prepared with a fluorophore at one extremity and a quencher group at the other (Meldal *et al* Methods in molecular biology 1998,87). The substrate can be identified using a strategy described in Apletalina *et al* ( JBC (1998)273, 41, 26589-95). For each

hexapeptide library, the identity of one residue at one position remains constant while the rest is randomized (for a total of  $6 \times 20 = 120$  individual libraries). Each library is made-up of 3.2 million different members and is identified both by the position of the constant residue along the hexapeptide, and its identity. The NL-enzyme is added to each library and the fluorescence is recorded. The data is organized to identify the libraries producing the most fluorescence for each position along the hexapeptide. This arrangement suggests the identity of important residues at each position along the hexapeptide. Hexapeptide representing the best suggestions are prepared and tested in a similar fashion. From this set, the hexapeptide with the best fluorescence is selected.

- set up enzymatic assays. An enzymatic assay consists in the addition of the above-identified substrate to the enzyme in constant conditions of pH, salts, temperature and time. The resulting solution is assayed for the hydrolysed peptide or for the intact peptide. This assay can be realized with specific antibodies, HPLC or, when self-quenched fluorescence tagged peptides are used (Meldal et al), by the appearance of fluorescence. The enzyme may be in solution or attached to a solid substrate;

- identify inhibitors. Inhibitors can be identified from synthetic libraries, biota extracts and from rationally designed inhibitors using X-ray crystallography and substituent activity relationships. Each molecule or extract fraction is tested for inhibitory activity using the enzymatic test described above. The molecule responsible for the largest inhibition is further tested to determine its pharmacological and toxicological properties following known procedures. The inhibitor with the best distribution, pharmacological action combined with low toxicity will be selected for drug manufacturing. Pharmaceutically acceptable formulation of the inhibitor or its acceptable salt will be prepared by mixing with known excipients to produce tablets, capsules or injectable solutions. Between 1 and 500mg of the drug is administered to the patients;

- inject the native or soluble purified NL-enzymes into subjects. In the case of disease or pathologies caused by a lack or decrease in NL activity, the purified NL could be injected intravenously or otherwise in patients. Alternatively, immobilized NL-enzymes could be introduced at the site of orthopedic surgery or implantation of devices in bones or dental tissues.

### Secretion of foreign proteins and peptides

As shown in the present work, the amino-terminal domain of NL-1 (from the initiator methionine to the furin site) can be used to promote the secretion of a foreign protein (in this case the ectodomain of NL-3 and  $\beta$ -endorphin).

The amino-terminal domain of NL-1 but also of other naturally occurring soluble NL-enzymes could be used to:

- promote production and secretion of foreign proteins. This can be achieved by genetically fusing sequences coding for said foreign proteins downstream from and in phase with the amino-terminal of NL-1. These chimeric constructs could be introduced with the help of appropriate vectors in any of the expression systems mentioned above for protein production and secretion;
- promote production and secretion of bioactive peptides. Sequences encoding small bioactive peptides such as but not exclusively  $\beta$ -endorphin, the enkephalins, substance P, atrial natriuretic peptide (ANF) and osteostatine, could be fused immediately downstream and in phase the furin site of NL-1. These DNA constructs could be used as described above to produce bioactive peptides.
- serve as model to design artificial (non-naturally occurring) proteins or protein segments (protein vectors) to promote secretion of proteins or peptides. These protein vectors can be constructed to resemble a secreted protein. In this case they would be assembled of an endoplasmic reticulum signal peptide, a spacer of varying length and a furin cleavage site to which the protein or peptide destined for secretion can be fused. The total length of the spacer, furin cleavage site and protein or peptide destined for secretion must be at least 70 amino acid residues. Alternatively, such protein vectors could be assembled to resemble a type II membrane protein. In this case they would comprise from the amino to the carboxy-terminus a cytosolic domain of varying length, a transmembrane domain that also acts as a signal peptide, an extracellular segment of varying length and a furin cleavage site to which the protein or peptide destined for secretion can be fused. The total length of the extracellular segment, furin cleavage site and protein or peptide destined for secretion must be at least 70 amino acid residues.

### Therapeutic applications of NL-enzymes

The inappropriate processing of endogenous peptides causes several diseases. The inappropriate processing may result from pathologic

concentration of the enzyme itself, its substrate or other elements of the biochemical machinery downstream from the controlling enzyme. In this context it is possible to help the patient by managing the activity of the controlling enzyme.

- 5        -        NL-enzymes have been localized to the brain and may be involved in the improper processing of  $\beta$ -amyloid precursor. Inhibitions of this process by drugs prepared as above, will help patients with Alzheimer disease as well as other patient suffering from diseases caused by plaque formation;
- 10       -        NL-enzymes may be involved in the improper processing of other peptides involved in neurological diseases, pain or psychiatric disorders. Appropriately designed inhibitors will help in the management of such diseases;
- 15       -        NL-1 is found in testis and is associated with spermatozoid maturation. Peptides improperly processed by the enzyme may lead to infertility. The addition of NL-1 ex-vivo to seminal liquid or immature spermatozoids taken directly from testis during an in-vitro fertilization procedure will increase fertility. Conversely, the use of a small-molecule inhibitor or removal of NL-1 with an antibody could increase fertility during an in-vitro fertilization procedure. The administration of a NL-1 inhibitor may increase or decrease the fertility potential. This inhibitor is formulated and administered as described above.
- 20       -        NL-3 is found in ovaries and may be involved in the processing of a peptide involved in the maturation of eggs. The addition of NL-3 ex-vivo to immature eggs taken directly from ovaries during an in-vitro fertilization procedure will increase fertility. Conversely, the use of a small-molecule inhibitor or removal of NL-3 with an antibody could increase fertility during an in-vitro fertilization procedure. This inhibitor is formulated and administered as described above;
- 25       -        NL-3 is found in bones. The improper processing of peptides by the enzyme may result in bone disease or abnormal phosphate metabolism. Administration of an inhibitor, as described above, will allow the disease management.
- 30       -        NL-3 is found in bones. The improper processing of peptides by the enzyme may result in bone disease or abnormal phosphate metabolism. Administration of an inhibitor, as described above, will allow the disease management.

35

TABLE I

Extend of amino acid sequence identity between members of the NEP-like family

	hNEP	hPEX	hECE-1A	hECE-2	hKELL	sNL-1	hNL-2	hNL-3
hNEP	100*							

5

hPEX	35	100						
hECE-1A	39	38	100					
hECE-2	36	37	62	100				
hKELL	23	24	30	31	100			
sNL-1	55	39	39	39	26	100		
hNL-2	54	39	39	39	26	77	100	
hNL-3	35	32	37	37	28	36	34	100

\*: percentage of sequence identity

TO P 230 634 E F 660

## REFERENCE LIST

- Almenoff, J., Teirstein, A.S., Thornton, J.C., and Orlowski, M. (1984) *J. Lab. Clin. Med.* **103**, 420-431
- 5 Anderson, A.D., Thomas, L., Hayflick, J.S., and Thomas, G. (1993) *J. Biol. Chem.* **268**, 24887-24891
- Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., and Smith, J.A. (1988). *Current protocols in molecular biology* (New York: Wiley Interscience).
- Aviv, R., Gurbanov, K., Hoffman, A., Blumberg, S., and Winaver, J. (1995) *Kidney Int.* **47**, 855-860
- 10 Bateman, R.C., Jackson D., Slaughter, C.A., Unnithan, S., Chai, Y.G., Moomaw, C., and Hersh, L.B. (1989) *J. Biol. Chem.* **264**, 6151-6157
- Bawab, W., Aloyz, R.S., Crine, P., Roques, B.P., DesGroseillers, L. (1993) *Biochem. J.* **296**, 459-465
- 15 Beaumont, A., Le Moual, H., Boileau, G., Crine, P., and Roques, B.P. (1991). Evidence that both arginine 102 and arginine 747 are involved in substrate binding to neutral endopeptidase (EC 3.4.24.11). *J. Biol. Chem.* **266**, 214-220.
- Benjannet, S., Savaria, D., Laslop, A., Munzer, J.S., Chrétien, M., Marcinkiewicz, M., and Seidah, N.G. (1997) *J. Biol. Chem.* **272**, 26210-26218.
- Chen, C. and Okayama, H. (1987) *Mol. Cell Biol.* **7**, 2745-2752
- 20 Chidiac, P., Nouet, S., and Bouvier, M. (1996) *Mol. Pharmacol.* **50**, 662-669
- Corvol, P. and Williams, T.A. (1997). Biochemical and molecular aspects of angiotensin I-converting enzyme. In *Cell-surface peptidases in health and disease*. A.J. Kenny and C.M. Boustead, eds. (Oxford, UK: BIOS Scientific Publishers Ltd), pp. 99-117.
- 25 Crine, P., Dion, N., and Boileau, G. (1997). Endopeptidase-24.11. In *Cell-Surface Peptidases in Health and Disease*. A.J. Kenny and C.M. Boustead, eds. (Oxford: BIOS Scientific Publishers), pp. 79-98.
- Crine, P., LeGrimellec, C., Lemieux, E., Labonté, L., Fortin, S., Blachier, A. and Aubry, M. (1985) The production and characterization of a monoclonal antibody specific for the 94000 dalton enkephalin-degrading peptidase from rabbit kidney brush border. *Biochem. Biophys Res. Commun.* **131**, 255-261.
- 30 Deschodt-Lanckman, M., Michaux, F., de Prez, E., Abramowicz, D., Vanherweghem, J.L., and Goldman, M. (1989) *Life Sci.* **45**, 133-141
- Devault, A., Nault, C., Zollinger, M., Fournié-Zaluski, M.-C., Roques, B.P., Crine, P., and Boileau, G. (1988a). Expression of neutral endopeptidase (enkephalinase) in heterologous COS-1 cells. Characterization of the recombinant enzyme and evidence for a glutamic acid residue at the active site. *J. Biol. Chem.* **263**, 4033-4040.
- 35 Devault, A., Sales, V., Nault, C., Beaumont, A., Roques, B.P., Crine, P., and Boileau,



- G. (1988b). Exploration of the catalytic site of endopeptidase 24.11 by site-directed mutagenesis. Histidine residues 583 and 587 are essential for catalysis. *FEBS Lett.* **231**, 54-58.
- Dion, N., Le Moual, H., Crine, P., and Boileau, G. (1993). Kinetic evidence that His-711 of neutral endopeptidase 24.11 is involved in stabilization of the transition state. *FEBS Lett.* **318**, 301-304.
- Dion, N., Le Moual, H., Fournié-Zaluski, M.C., Roques, B.P., Crine, P., and Boileau, G. (1995). Evidence that Asn<sup>542</sup> of neprilysin (EC 3.4.24.11) is involved in binding of the P<sub>2</sub>' residue of substrates and inhibitors. *Biochem.J.* **311**, 623-627.
- Holmes, M.A. and Matthews, B.W. (1982). Structure of thermolysin refined at 1.6 Å resolution. *J.Mol.Biol.* **160**, 623-639.
- Hooper, N.M. (1994). Families of zinc metalloproteases. *FEBS Lett.* **354**, 1-6.
- Howard, T.E., Shai, S.Y., Langford, K.G., Martin, B.M., Bernstein, K.E. (1990) *Mol. Cell. Biol.* **10**, 4294-4302
- Ikeda, K., Emoto, N., Raharjo, S.B., Nurhantari, Y., Saiki, K., Yokoyama, M., Matsuo, M. (1999) *J. Biol. Chem.* **274**, 32469-32477
- Jeannotte, L., Burbach, J.P., Drouin, J. (1987) *Mol. Endocrinol.* **1**, 749-757
- Johnson, A.R., Coalson, J.J., Ashton, J., Larumbide, M., and Erdos, E.G. (1985) *Am. Rev. Respir. Dis.* **132**, 1262-1267
- Johnson, G.D., Stevenson, T., and Ahn, K. (1999) *J. Biol. Chem.* **274**, 4053-4058
- Endocrinol.* **3**, 1191-1196
- Kenny, J. (1993). Endopeptidase-24.11: Putative substrates and possible roles. *Biochem.Soc.Trans.* **21**, 663-668.
- Kew, D., Jin, D.F., Kim, F., Laddis, T., and Kilpatrick, D.L. (1989) *Mol. J. Biol Chem.* **266**, 214-220
- Kew, D., Muffly, K.E., and Kilpatrick, D.L. (1990) *Proc. Natl. Acad. Sci. U.S.A* **87**, 9143-9147
- Kilpatrick, D.L., Borland, K., and Jin, D.F. (1987) *Proc. Natl. Acad. Sci. U.S.A.* **84**, 5695-5699
- Kilpatrick, D.L. and Millette, C.F. (1986) *Proc. Natl. Acad. Sci. U.S.A* **83**, 5015-5018
- Kozak, M. (1986) *Cell* **44**, 283-292
- Lafrance, M.H., Vezina, C., Wang, Q., Boileau, G., Crine, P., and Lemay, G. (1994) *Biochem. J.* **302**, 451-454.
- Lanctôt, C., Fournier, H., Howell, S., Boileau, G., and Crine, P. (1995) *Biochem. J.* **305**, 165-171
- Le Moual, H., Devault, A., Roques, B.P., Crine, P., and Boileau, G. (1991). Identification of glutamic acid 646 as a zinc-coordinating residue in endopeptidase-24.11. *J.Biol.Chem.* **266**, 15670-15674.
- Le Moual, H., Dion, N., Roques, B.P., Crine, P., and Boileau, G. (1994). Asp650 is

- crucial for catalytic activity of neutral endopeptidase 24-11. *Eur.J.Biochem.* 221, 475-480.
- 5 Lemay, G., Waksman, G., Roques, B.P., Crine, P., and Boileau, G. (1989). Fusion of a cleavable signal peptide to the ectodomain of neutral endopeptidase (EC 3.4.24.11) results in the secretion of an active enzyme in COS-1 cells. *J.Biol.Chem.* 264, 15620-15623.
- Logeat, F., Bessia, C., Brou, C., LeBail, O., Jarriault, S., Seidah, N.G., and Israël, A. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 8108-8112.
- Malfroy, B., and Schwartz, J.C. (1982) *Biochem. Biophys. Res.Com.* **106**, 276-285
- 10 Marie-Claire, C., Ruffet, E., Antonczak, S., Beaumont, A., O'Donohue, M., Roques, B.P., and Fournié-Zaluski, M.C. (1997). Evidence by site-directed mutagenesis that arginine 203 of thermolysin and arginine 717 of neprilysin (neutral endopeptidase) play equivalent critical roles in substrate hydrolysis and inhibitor binding. *Biochemistry* 36, 13938-13945.
- 15 Mehta, N.D., Don, J., Zinn, S.A., Millette, C., Wolgemuth, D.J., and Kilpatrick, D.L. (1994) *Endocrinology* **135**, 1543-1550
- Milhiet, P.E., Chevallier, S., Corbeil, D., Seidah, N.G., Crine, P., and Boileau, G. (1995) *Biochem. J.* **309**, 683-688
- Monsees, T.K., Gornig, M., Schill, W.B., and Miska, W. (1998) *Andrologia* **30**, 185-191
- 20 Nakayama, K. (1997) *Biochem. J.* **327**, 625-635
- Nakayama, K., Kim, W.S., Torii, S., Hosaka, M., Nakagawa, T., Ikemizu, J., Baba, T., and Murakami, K. (1992) *J. Biol. Chem.* **267**, 5897-5900
- Phelan, M.C., Rogers, R.C., Clarkson, K.B., Bowyer, F.P., Levine, M.A., Estabrooks, L.L., Severson, M.C., and Dobyns, W.B. (1995). Albright hereditary
- 25 osteodystrophy and del(2) (q37.3) in four unrelated individuals. *Am.J.Med.Genet.* 58, 1-7.
- Raut, R., Rouleau, J.L., Blais, C. Jr, Gosselin, H., Molinaro, G., Sirois, M.G., Lepage, Y., Crine, P., and Adam, A. (1999) Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11. *Am. J Physiol.* 276, H1769-H1779.
- 30 Ruchon, A.F., Marcinkiewicz, M., Siegfried, G., Tenenhouse, H.S., DesGroseillers, L., Crine, P., and Boileau, G. (1998). Pex mRNA is localized in developing mouse osteoblasts and odontoblasts. *J.Histochem.Cytochem.* 46, 459-468.
- Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989). *Molecular cloning, a laboratory manual* (New-York: Cold Spring Harbor Laboratory Press).
- 35 Schacke, H., Schumann, H., Hammami-Hausli, N., Raghunath, M., and Bruckner-Tuderman, L. (1998) *J. Biol. Chem.* **273**, 25937-25943
- Seidah, N.G. and Chrétien, M. (1995). Pro-protein convertases of subtilisin/kexin family. *Methods Enzymol.* 244, 175-188.

- Seidah, N.G., Day, R., Hamelin, J., Gaspar, A., Collard, M.W., and Chretien, M. (1992) *Mol. Endocrinol.* **6**, 1559-1570
- Seidah, N.G., Hamelin, J., Mamarbachi, M., Dong, W., Tadros, H., Mbikai, M., Chretien, M., and Day, R. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 3388-3393
- 5 Soleilhac, J.M., Lafuma, C., Porcher, J.M., Auburtin, G., and Roques, B.P. (1996) *Eur. J. Clin. Invest.* **26**, 1011-1017
- Torii, S., Yamagishi, T., Murakami, K., and Nakayama, K. (1993) *FEBS Lett.* **316**, 12-16
- 10 Turner, A.J. (1997a). Endothelin-converting enzymes. In *Cell-surface peptidases in health and disease*. A.J. Kenny and C.M. Boustead, eds. (Oxford, UK: BIOS Scientific Publishers Ltd.), pp. 137-153.
- Turner, A.J. and Tanzawa, K. (1997b). Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. *FASEB J.* **11**, 355-364.
- Turner, A.J., and Murphy, L. (1996) *Biochem. Pharmacol.* **51**, 91-102
- 15 Turner, A.J., Matsas, R., and Kenny, A.J. (1985) *Biochem. Pharmacol.* **34**, 1347-1356
- Vijayaraghavan, J., Kim, Y.-A., Jackson, D., Orłowski, M., and Hersh, L.B. (1990). Use of site-directed mutagenesis to identify valine-573 in the S'1 binding site of rat neutral endopeptidase 24.11 (enkephalinase). *Biochemistry* **29**, 8052-8056.

T01230"6288T650

09/913329

EPO - DG 1

518 Rec'd PCT/PTO 13 AUG 2001

13. 04. 2001

WHAT IS CLAIMED IS:

(82)

1. A method for obtaining a Neprilysin-like (NEP-like) metallopeptidase which comprises the following steps:
  - selecting a primer in C-terminus of the His-Glu-Xaa-Xaa-His (where Xaa represents any amino acid) with a degenerate nucleotide sequence complementary to at least the Gly-Glu-Asn-Ile-Ala-Asp amino acid sequence of known NEP-like metallopeptidases with sufficient binding capacity;
  - selecting a primer in N-terminus of the His-Glu-Xaa-Xaa-His (where Xaa represents any amino acid) with a degenerate nucleotide sequence complementary to a conserved amino acid sequence with preferably 80% homology with known NEP-like metallopeptidases and sufficient binding capacity;
  - contacting said primer with tissue nucleic acids to yield PCR products;
  - selecting said PCR products that contain the His-Glu-Xaa-Xaa-His motif; and
  - completing the sequence of said selected PCR products with standard methods.
2. A metallopeptidase sharing about 80% homology with the amino acid sequence shown in Figure 3.
3. A metallopeptidase which is soluble sharing about 80% homology with the amino acid sequence in C-terminus of the furin site shown in Figure 3.
4. A metallopeptidase which is soluble sharing about 80% homology with the amino acid sequence shown in Figure 3 and with an enzymatic activity capable of degradation of known Neprilysin substrates, preferably Tyrosyl-[3,5-<sup>3</sup>H1](D-Ala<sub>2</sub>)-Leu<sub>5</sub>-enkephalin and bradykinin.
5. A composition comprising a metallopeptidase as defined in any one of claims 2-4.

6. A nucleic acid encoding a metallopeptidase as defined in any one of claims 2-4.
7. An antibody directed against a metallopeptidase as defined in any one of claims 2-4.
- 5 8. A method for obtaining a substrate of a metallopeptidase as defined in any one of claims 2-4, which comprises the steps of:
- contacting said metallopeptidase with a molecule or extract; and
  - assaying the resulting solution for a decrease in said molecule or extract, when compared with the same but in absence of said metallopeptidase, as an indication of the presence of said substrate.
- 10 9. A method for obtaining an inhibitor of a metallopeptidase as defined in any one of claims 2-4, which comprises the steps of:
- contacting said metallopeptidase with a molecule or extract in the presence of a substrate selected known NEP substrates, preferably Tyrosyl-[3,5-<sup>3</sup>H1](D-Ala<sub>2</sub>)-Leu<sub>5</sub>-enkephalin and bradykinin; and
  - assaying the resulting solution for an increase in said substrate, when compared with the same but in absence of said metallopeptidase, as an indication of the presence of said inhibitor.
- 15 10. \* An inhibitor obtained from the method of claim 9.
- 20 11. The use of a known NEP inhibitor or an inhibitor as defined in claim 10 to control the enzymatic activity of a metallopeptidase as defined in any one of claims 2-4.
12. The use of a known NEP inhibitor or an inhibitor as defined in claim 10 to manage disease relating to the physiological status of the cardiovascular system, the central nervous system, the spleen, the liver, the kidney, the male reproductive system or the maturation of spermatozoa.
- 25 13. The use of a metallopeptidase as defined in any one of claims 2-4 to manage disease relating to the physiological status of the cardiovascular

T01230" 000000147

system, the central nervous system, the spleen, the liver, the kidney, the male reproductive system or the maturation of spermatozoa.

- 5
14. A recombinant vector comprising 80% homology with the nucleic acid encoding the N-terminal part of the amino acid sequence shown in Figure 3, which N-terminal part terminates with a furin-recognition sequence.
15. A method for producing a soluble form of a protein, polypeptide or part thereof which comprises:
- obtaining nucleic acids encoding said protein, polypeptide or part thereof;
  - 10 - fusing said nucleic acids in phase with an N-terminal fragment wherein said N-terminal fragment comprises a cleavable furin-like site located in C-terminus past the transmembrane region or is an N-terminal part as defined in claim 14;
  - 15 - having the fused nucleic acids to be expressed in a host cell which expresses or is made to express furin in the presence of a culture medium; and
  - recovering said soluble form in the culture medium.
- 20
16. A protein, polypeptide or part thereof produced by the method defined in claim 15, wherein said protein, polypeptide or part thereof is a metallopeptidase sharing about 80% homology with the region in C-terminus of the putative furin site of the amino acid sequence shown in Figure 4.
- 25
17. A metallopeptidase sharing about 80% homology with the region in C-terminus of the putative furin site of the amino acid sequence shown in Figure 4.
18. A metallopeptidase sharing about 80% homology with the region in C-terminus of the putative furin site of the amino acid sequence shown in Figure 4 and with an enzymatic activity capable of degradation of known

NEP substrates, preferably Tyrosyl-[3,5-<sup>3</sup>H1](D-Ala<sub>2</sub>)-Leu<sub>5</sub>-enkephalin and bradykinin.

19. A composition comprising a metallopeptidase as defined in any one of claims 16-18.
- 5 20. A nucleic acid encoding a metallopeptidase as defined in any one of claims 16-18.
21. An antibody directed against a metallopeptidase as defined in any one of claims 16-18.
22. A method for obtaining a substrate of a metallopeptidase as defined in  
10 any one of claims 16-18, which comprises the steps of:
  - contacting said metallopeptidase with a molecule or extract; and
  - assaying the resulting solution for a decrease in said molecule or extract, when compared with the same but in absence of said metallopeptidase, as an indication of the presence of said substrate.
- 15 23. A method for obtaining an inhibitor of a metallopeptidase as defined in any one of claims 16-18, which comprises the steps of:
  - contacting said metallopeptidase with a molecule or extract in the presence of a substrate selected from known NEP substrates or a protein, polypeptide or part thereof produced by the method of claim 15,  
20 preferably Tyrosyl-[3,5-<sup>3</sup>H1](D-Ala<sub>2</sub>)-Leu<sub>5</sub>-enkephalin and bradykinin; and
  - assaying the resulting solution for an increase in said substrate, when compared with the same but in absence of said metallopeptidase, as an indication of the presence of said inhibitor.
24. An inhibitor obtained from the method of claim 23.
- 25 25. The use of a known NEP inhibitor or an inhibitor as defined in claim 24 to control the enzymatic activity of a metallopeptidase as defined in any one of claims 16-18.

051339-08101  
TOP SECRET

26. The use of a known NEP inhibitor or an inhibitor as defined in claim 24 to manage disease relating to the physiological status of the cardiovascular system, the central nervous system, the spleen, the liver, the kidney, the male reproductive system or the maturation of spermatozoa.
- 5 27. The use of a metallopeptidase as defined in any one claims 16-18 to manage disease relating to the physiological status of the cardiovascular system, the central nervous system, the spleen, the liver, the kidney, the male reproductive system or the maturation of spermatozoa.
28. A method as defined in claim 15, wherein said protein, polypeptide or part thereof is beta-endorphin.
- 10 29. A recombinant host cell capable of expressing a protein, polypeptide or part thereof transplanted in a mammal to manage a disease, physiological process or pain.
30. A metallopeptidase sharing about 80% homology with the amino acid sequence located in the C-terminus of the predicted transmembrane domain of the amino acid sequence shown in Figure 5 which has been produced by the method of claim 15, by fusing in frame a cleavable signal peptide in N-terminus of said amino acid sequence or by transforming said predicted transmembrane domain into a cleavable signal peptide.
- 15 31. A composition comprising a metallopeptidase as defined in claim 30.
32. An antibody directed against a metallopeptidase as defined in claim 30.
33. A method for obtaining a substrate of a metallopeptidase as defined in claim 30, which metallopeptidase shares about 80% homology with the C-terminal region of the predicted transmembrane domain of the amino acid sequence shown in Figure 5, comprising the steps of:
- 25 -- contacting said metallopeptidase with a molecule or extract; and

TO 280 622660



-- assaying the resulting solution for a decrease in said molecule or extract, when compared with the same but in absence of said metallopeptidase, as an indication of the presence of said substrate.

5 34. A method for obtaining an inhibitor of a metallopeptidase sharing about 80% homology with the C-terminal region of the predicted transmembrane domain of the amino acid sequence shown in Figure 5, which comprises the steps of:

-- contacting said metallopeptidase with a molecule or extract in the presence of a substrate produced by the method of claim 33; and

10 -- assaying the resulting solution for an increase in said substrate, when compared with the same but in absence of said metallopeptidase, as an indication of the presence of said inhibitor.

35. An inhibitor obtained by the method of claim 34.

15 36. The use of an inhibitor as defined in claim 35 to control the enzymatic activity of the metallopeptidase sharing about 80% homology with the C-terminal region of the predicted transmembrane domain of the amino acid sequence shown in Figure 5.

20 37. The use of an inhibitor as defined in claim 35 to manage disease relating to the physiological status of the central nervous system, the spleen or the bones.

38. The use of a metallopeptidase as defined in claim 30 to manage disease relating to the physiological status of the cardiovascular system, the central nervous system, the spleen or the bones.

1/22

```

      1          10          20          30
NEP1-HU MGK.....SESQMDITDINT..PKPKKKQRWTPLEI.....SLSVLVLLL
        *                *       *               *
PEX-HUM MEA.....ETG....SSVET..GKKANRGTRIALVV.....FVGGLTVLGG
        **              *           *                   * *
KELL-HU MEGGDQSEEEPRERSQAGGMGTLSQESTPEERLPVEGSRPWAV...ARRVLTAILIL.
        +                *             *   *   *   *         *
ECE1-HU MSTYKRATLDEEDLVDSLSEGDAYPNGLQVNFHSPRSGQRCWAARTQVEKRLVVLVLLA

consens  M                                T                    P                      L

```

	40	50	60	70	80	90
NEP1-HU	TIIAVTMIALYA.TYDD...	GICKSSDCIKSAARLIQ	NMDATTEPCTDFFKYAC	GGWLKR		
	**	*	*	**	**	**
PEX-HUM	TILFLVSQGLLSLQAKQ...	EYCLKPECIEAAAILSK	VNLSVDP	PCDNFFRFACD	GWISN	
	*	*	*	*	*	*
KELL-HU	.GLLLCFSVLLFYNFQNC	GRPRCETS	VLCLDRDHYLASGNT	SVAPCTDFFSFACG...	RA	
	**	*	*	*	*	*
ECE1-HU	AGLVACLAALGI.QYQTR	SPSVCLSEACVSVTSS	ILSSMDPTVDPCHDFF	SYACGGWIK		
consens	L	L	C	C	L	V PC DFF ACGGW

	100	110	120	130	140	150
NEP1-HU	NVIPETSSRYGNFDILRDELEVVLKDVLPQEP..KTEDIVAVQKAKALYRSCINESAIDSR					
	* * * *	** **	** *	*	* * * * *	* * * *
PEX-HUM	NPIPEDMPsyGVYPWLRHNVDLKLKELLEKSISRRTDEAIQKAKILYSSCMNEKAIEKA					
		*	*	*	*	*
KELL-HU	KETNNS.....FQELATKNKNRLRRILEVQ.NSWHPGSGEEKAFQFYNSCMDTLAIEAA					
		* * *	**		* * *	* * *
ECE1-HU	NPVPDGHRSRWGTFSNLWEHNQAI IKHLLENS.TA.SVSEAERKAQVYYRACMNETRIEEL					
consens	N P	G F L	LK LE	A KA	Y SCMNE AIE	

	160	170	180	190	200
NEP1-HU	GGEPLLKLLPDI.YGWP..VATENWEQKYGAS.WTAEKAI	QLN	SKYGKKVLINL	FGV	TD
	*** *	**	*	*	* * * * *
PEX-HUM	DAKPLLHILRHSPFRWPVLESNIGPEGVWSE	KFS	LLQTLATFRGQYS	NSV	FIRLYVSPD
	**		* * *	**	* * * *
KELL-HU	GTGPLRQVIEEL.....GGWRISGK	WTS	LNFN..RTLRL	MSQYGH	FPFFRAYL
	** ** *	*** * * *	**	**	* *** *
ECE1-HU	RAKPLMELIERL.....GGWNITGP	WAK	DNFQ..DTLQV	TAHYRTS	PF
consens	PL		G W F	TL	Y F YV D

	220	230	240	250	260
NEP1-HU	DKNSVNHVIIHIDQPRGLPSR.DYYECTGIYKEACTAYVDFMISVARLIRQEERLPI.DE				
	** * *	** * *	*	** *	* *
PEX-HUM	DKASNEHILKLDQATLSLAVREDYLDNSTEAKSYRDALYKFMVDTAVL.....LGA.NS				
	**	*	* *	*	**
KELL-HU	PASPHTPVIQIDQPEFDVPLKQDQEQKI.YAQIFRE.YLTYLNQLGTL.....LGG.DP				
	*** **	*	*	** * *** *	*** *
ECE1-HU	SKSNSNSNVIQVDQSGGLGPSRDYYLNKTENEKVLTG.YLNYMVQLGKL.....LGGGDE				
consens	K S VI DQ L L P R DY		K	Y M	L LG D

2/22

270 280 290 300 310 320  
 NEP1-HU NQLALEMNKVMELEKEIANATAKPEDRNDPMLLYNKMTLAQIQNNFSLEINGKPFPSWLN  
 \* \* \* \* \*  
 PEX-HUM SRAEHDMKSVLRLEIKIAEIMIPHENRTSEAMY.NKMNISELSAMIP.....QFDWLGY  
 \* \* \* \* \*  
 KELL-HU SKVQEHSSLSISITSRLFQFLRPLEQRRRAQGKLFQMVTIDQLKEMAP.....AIDWLSC  
 \* \* \* \* \*  
 ECE1-HU EAIRPQMQQILDFTALANITIPQEKRRDEELIYHKVTAELQTLAP.....AINWLPF  
 \* \* \* \* \*  
 consensus M E A P E R K T L P WL

330 340 350 360 370 380  
 NEP1-HU TNEIMSTVNISITNEEDVVVYA...PEYLTCLKPILTKYSARDLQNLMSWRFIMDLVSS  
 \* \* \* \* \*  
 PEX-HUM IKKVIDTRLYPHLKDISPENVVVRVPQYFKDLFRILGSRKKTIANYLWVRMVYSRIPN  
 \* \* \* \* \*  
 KELL-HU LQATFTPMSPSLVVDHVEYL...KNMSQLVEEMLLKQRDFLQSHMILGLVVTLSPA  
 \* \* \* \* \*  
 ECE1-HU LNTIFYPVEINESEPIVVYDKEYL...EQISTLINT...TDRCLLNNYMIWNLVKRTSSF  
 \* \* \* \* \*  
 consensus V L L N M W V

390 400 410 420 430  
 NEP1-HU LSRTYKESR...NAFRKALYGTT.SETATWRRRCANYVNGNMENAVGRLYVEAAFAGESK  
 \*\*\* \* \* \* \*  
 PEX-HUM LSRRFQYRW...LEFSRVIQGT.TLLPQWDKCVNFIESALPYVVGKMFVDVYFQEDKK  
 \* \* \* \* \*  
 KELL-HU LDSQFQEARRKLSQKLRELTEQPPMPARPRWMKCVEETGTFFETLAALFVREAFGPSTR  
 \* \* \* \* \*  
 ECE1-HU LDQRFQDA...DEKFMEVMYGTKKTCPLRWKFCVSDTENNLFALGPMFVKATFAEDSK  
 \* \* \* \* \*  
 consensus L FQ F GT P W CV G FV F K

440 450 460 470 480 490  
 NEP1-HU HVVEDLIAQIREVFIQTLD.DLTWMDAETKKRAEEKALAIKERIGYPDDIVSNDNKLNE  
 \* \* \* \* \*  
 PEX-HUM EMMEELVEGVRWAFIDMLEKENEWMDAGTRKKAKEKARAVLAKVGYPE.FIMNDTHVNED  
 \* \* \* \* \*  
 KELL-HU SAAMKLFTAIRDALITRLR.NLPWMNEETONMAQDKVAQLQVEMGASE.WALKPELARQE  
 \* \* \* \* \*  
 ECE1-HU SIATEIILEIKKAFFESLS.TLKWMDEETRKSAKEKADAIYNMIGYPN.FIMDPKELDKV  
 \* \* \* \* \*  
 consensus L IR AFI L L WMD ET A EKA A GYP  
 (4)  
 (1A/B)

500 510 520 530 540 550  
 NEP1-HU YLELNKYEDEYFENIIQNLKFSQSKQLKKLREKVDKDEWISGAADVNAFYSSGRNQIVFP  
 \* \* \* \* \*  
 PEX-HUM LKAIKFSEADYFGNVLQTRKYLAQSDFFWLKAVPKTEWFTNPTTVNAFYASTNQIRFP  
 \* \* \* \* \*  
 KELL-HU YND.IQLGSSFLQSVLSCVRSRRLRIVQSFLQPHQPQHRWKVSPWDVNAYYSVSDHVVFP  
 \* \* \* \* \*  
 ECE1-HU FNDYTAVPDLYFENAMRFFNFSWRVTADQLRKAPNRDQWSMTPPMVNAYYSPTKNEIVFP  
 \* \* \* \* \*  
 consensus YF N LR W P VNA YS N IVFP  
 (2A/B)

1 (cont'd)

0913329-08101  
T0280-62E155

3/22

	560	570	580	590	600	610
NEP1-HU	AGILQPPFFSAQQ.SNSLNYGGIGMVIGHEITHGFDDNGRNFNKDGLVDWWTQQSASNF					
	** ** *	** ** *	** ** *	** ** *	** ** *	** ** *
PEX-HUM	AGELQKPPFFWGTEYPRSLSYGAIGVIVGHEFTHGFDDNNGRKYDKNGNLDPWWSTEESEKF					
	** ** *	** ** *	** ** *	** ** *	** ** *	** ** *
KELL-HU	AGLLQPPFFHPGY.PRAVNFGAAGSIMAHELLHIFYQL...LLPGGCL....ACDNHAL					
	** ** *	** ** *	** ** *	** ** *	** ** *	** ** *
ECE1-HU	AGILQAPFYTRSS.PKALNFGGIGVVVGHETHAFDDQGREYDKDGNLRPWWKNSSVEAF					
consens	AG LQ PFF	P L N G I G	G H E T H F D	G R	K G L W W	S F

	620	630	640	650	660	670
NEP1-HU	KEQSQCVMVYQYGNFSWDLAGGQHLNGINTLGENIADNGGLGQAYRAYQNYI..KKNNG.EE					
	** ** *	** ** *	** ** *	** ** *	** ** *	** ** *
PEX-HUM	KEKTKCMINQYSNYYWK.KAGLNVKGKRTLGENIADNGGLREAFRAYRKWINDRRQGLEE					
	* * *	* * *	* * *	* * *	* * *	* * *
KELL-HU	QEAPHLCKLRHYAAF..PLPSRTSFNDLSLTFLENAADVGGLAIALQAYSRL..LRHH.GE					
	* *	* *	* *	* * *	* * *	* *
ECE1-HU	KRQTECMVEQYSNY..SVNG.EPVNGRHTLGENIADNGGLKAAYRAYQNWV..KKNNG.AE					
				(B)		
consens	KE CM QY N		NG TL	GENIADNGGL	A RAY	G E

	680	690	700	710	720	730
NEP1-HU	KLLPGLDLNHKQLFFLNFAQVWCCTYRPEYAVNSIKTDVHSPGNFRIIGTLQNSAEFSEA					
	****	*****	* * *	*****	*** ** *	* * *
PEX-HUM	PLLPGITFTNNQLFFLSYAHVRCNSYRPEAAREQVQIGAHSPQFRVNGAISNFEEFQKA					
	**	* * *	* * *	*	**** * *	*
KELL-HU	TVLPSLDLSPQQIIFRSYAQVMCRKPSPQDSH....DTHSPPHLRVHGPLSSTPAFARY					
	* * *	* * *	*** *	* **	* * *	* * *
ECE1-HU	HSLPTLGLTNNQLFFLGFAQVWC SVRTPESSHEGLITDPHSPSRFRVIGSLSNSKEFSEH					
consens	LP L L	QLFFL	AQV C	PE	D HSP	FRV G LSN EF

	740	750
NEP1-HU	FHCRKNSYMNPEKK.CRVW	
	* * *	* * *
PEX-HUM	FNCPPNSTMNRGMDSCRLW	
	* *	* **
KELL-HU	FRCARGALLNPSSR.CQLW	
	*** *	* * *
ECE1-HU	FRCPPGSPMNPPHK.CEVW	
		(S)
consens	F C S MNP	C W

4/22

PRIMER	SEQUENCE
(1A)	5'-TGGATGGAT/CGA/CIGG/AIACIA/CA-3'
(1B)	5'-TGGATGGAT/CGA/CIGG/AIACIA/CG-3'
(2A)	5'-A/GTIGTITTT/CCCIGCIGGIA/GT/AIC/TTA/TCA-3'
(2B)	5'-A/GTIGTITTT/CCCIGCIGGIA/GT/AIC/TTG/CCA-3'
(3)	5'-AIIICCICCIA/TC/TA/GTCIGCIG/AC/TA/GTTT/CTC-3'
(4)	5'-GAT/CAAT/CT/CTIGAT/CGAA/GT/CTIAAT/CTGGATGG-3'
(5)	5'-T/CT/CACCAIATICT/GA/GCATCG/TT/CTTCATIGGG/ATG-3'

7#E-2

## Sequence of NL-1 cDNA from mouse

c9q9agdcagacgcgtctggaaccaccacagcctcg  
ctgctctactcccccggagccaccccttggccagctccaccacaacctggagacatccccactgacctgaccttaaggacttgaggaactgggaacacacagccttcagagctcgagagcag  
agacacaggagagtgacacagcttcagtctactaggcaacctgatctggggtccagctgacctctctccatgacctggggtctgggggtctagcgtctgccctccaccagaaacggcctgactggggaagctctgagagcccccagcggg

	met val glu arg ala gly trp cys arg lys lys ser pro gly phe val glu tyr gly leu met val leu leu leu leu leu leu leu	30
1	ATG GTG GAG AGA GCA GCC TGG TGT CGG AAG AAG TCC CCA GGC TTC GTG GAG TAT GGG CTG ATG GTG CTG CTG CTG TTG CTG GGA GCC	60
	ile val thr leu leu gly val phe tyr ser ile gly lys gln leu pro leu leu his phe ser trp asp glu arg thr val	
91	ATA GTG ACT CTG GGT GTC TTC TAC AGC ATA GGG AAG CAG CTG CCC CTC TTA ACT AGC CTG CTA CAC TTC TCC TGG GAT GAG AGG ACG GTT	90
	val lys arg ala leu arg asp ser ser leu lys ser asp ile cys thr thr acc acc cca agc tgt gtg ata gca gct gcc aga atc ctc gaa aac	
181	GTA AAA CGA GCC CTC AGG GAT TCA TCA CTG AAA AGT GAC ATC TGC TGC ACC ACC CCA AGC AGC TGT GTG ATA GCA GCT GCC AGA ATC CTC GAA AAC	120
	met asp gln ser arg asn pro cys glu asn phe tyr gln gln tyr ala cys gly gly trp leu arg his val ile pro glu thr asn ser	
271	ATG GAC CAA TCG AGG AAC CCC TGT GAA AAC TTC TAC CAG TAC GCC TGC GGA GGC TGG CTG AGG CAC CAC GTG ATC CCA GAG ACC AAC TCC	150
	arg tyr ser val phe asp ile leu arg asp glu leu val ile leu lys gly val leu glu asp ser thr ser gln his arg pro ala	
361	TAC AGC GTC TTT GAC ATC CTG CGG GAC GAG CTG GAG GTT ATC CTC AAA GGG GTG CTG GAG GAT TCC ACT TCC CAG CAT CGC CCG GCC	180
	val glu lys ala lys thr leu tyr arg ser cys met asn gln ser val ile glu lys arg asp ser glu pro leu leu ser val leu lys	
451	GTC GAG AAG GCC AAG ACA CTA TAT CGC TCC TGC ATG AAC CAA AGT GTG ATC GAG AAG AGA GAC TCT GAG CCC CTG AGC GTC TTA AAA	210
	met val gly gly trp pro val ala met asp lys trp asn gln thr met gly leu lys trp glu leu glu ala val leu asn	
541	GTA GGA GGT TGG CCT GTG GCC ATG GAT AAG TGG AAC GAG ACC ATG GGC CTC AAG TGG GAA CTG GAG CGA CAG TTG GCT GTG TTG AAC	240
	ser gln phe asn arg arg val leu ile asp leu phe ile trp asn asp gln asn ser ser arg his val ile tyr ile asp gln pro	
631	TCG CAG TTC AAC AGG CGG GTC CTC ATC GAC CTC TTC ATC TGG AAT GAC CAG AAC TCC AGC CGG CAT GTC ATC TAC ATA GAC CAG CCC	270
	thr leu gly met pro ser arg glu tyr tyr phe gln gln asp asn asn his lys val arg lys ala tyr leu glu phe met thr ser val	
721	ACC TTG GGC ATG CCA TCC CGG GAG TAC TAT TTC CAG GAG GAC AAC CAC AAC GGC AAA GCC TAC CTG GAG TTC ATG ACG TCA GTG	

FILE

6/22

ala thr met leu arg lys asp gln asn leu ser lys glu ser ala met val arg glu glu met ala glu val leu glu leu glu thr his  
 811 GCC ACT ATG CTT AGG AAA GAC CAG AAC CTG TCC AAG GAG AGC GCC ATG GTG CGG GAG GAG ATG GCG GAG CTG GAA CTG GAG ACG CAT  
 leu ala asn ala thr val pro gln glu lys arg his asp val thr ala leu tyr his arg met asp leu met glu leu gln glu arg phe  
 901 CTG GCC AAC GCC ACA GTC CCC CAG GAG AAA AGG CAT GAT GTC ACT GCC CTG TAC CAC CGA ATG GAC CTG ATG GAG CTA CAG GAA AGG TTT  
 gly leu lys gly phe asn trp thr leu phe ile gln asn val leu ser ser val glu val glu leu phe pro asp glu glu val val  
 991 GGT CTG AAG GGG TTT AAC TGG ACT CTC TTC ATA CAA AAC GTG TTG TCT TCT GTG GAA GTC GAG CTG TTC CCA GAT GAG GAG GTG GTC  
 tyr gly ile pro tyr leu glu asn leu glu asp ile ile asp ser tyr ser ala arg thr met gln asn tyr leu val trp arg leu val  
 1081 TAC GGC ATC CCC TAC CTG GAG AAT CTG GAG GAT ATC ATT GAT AGC TAC TCA GCA CGG ACC ATG CAG AAC TAC CTG GTA TGG CGC CTG GTG  
 leu asp arg ile gly ser leu ser gln arg phe lys glu ala arg val asp tyr arg lys ala leu tyr gly thr thr val glu glu val  
 1171 CTA GAT CGA ATT GGC AGC CTG AGC CAG AGA TTC AAA GAG GCG CGT GTG GAC TAC CGC AAG GCG CTG TAC GGC ACG ACC GTG GAG GAG GTA  
 arg trp arg glu cys val ser tyr val asn ser asn met glu ser ala val val gly ser leu tyr ile lys arg ala phe ser lys asp ser  
 1261 CGC TGG CGA GAG TGT GTC AGC TAT GTC AAC AGT AAC ATG GAG AGC GCC GTG GGC TCC CTC TAC ATC AAG CGG GCC TTC TCC AAG GAC AGC  
 lys ser thr val arg glu leu ile glu lys ile arg ser val phe val asp asn leu asp glu leu asn trp met asp glu glu ser lys  
 1351 AAG AGC ACG GTC AGA GAG CTG ATT GAG AAG ATA AGG TCC GTG TTT GTG GAT AAC CTG GAT GAG CTG AAC TGG ATG GAC GAG GAA TCC AAG  
 lys lys ala gln glu lys ala met asn ile arg glu gln ile gly tyr pro asp tyr ile leu glu asp asn asn lys his leu asp glu  
 1441 AAG AAG GCC CAG GAA AAG GCC ATG AAT ATA CGG GAA CAG AAT GGC TAC CCT GAC TAC ATT TTG GAA GAT AAC AAT AAA CAC CTG GAT GAG  
 glu tyr ser ser leu thr phe tyr glu asp leu tyr phe glu asn gly leu gln asn leu lys asn asn ala gln arg ser leu lys lys  
 1531 GAA TAC TCC AGT TTG ACT TTC TAT GAG GAC CTG TAT TTT GAG AAC GGA CTT CAG AAC CTC AAG AAC AAT GCC CAG AGG AGC CTC AAG AAG  
 leu arg glu lys val asp gln asn leu trp ile ile gly ala ala val val asn ala phe tyr ser pro asn arg asn gln ile val phe  
 1621 CTT CGG GAA AAG GTG GAC CAG AAT CTC TGG ATC ATC GGC GCT GCA GTG GTC AAT GCA TTC TAC TCC CCA AAC AGA AAC CAG ATC GTC TTT

TTTT - E (cont'd)

7/22

600  
pro ala gly ile leu gln pro phe phe ser lys asp gln pro gln ser leu asn phe gly gly ile gly met val ile gly his  
1711 CCA GCA GGG ATT CTC CAG CCG CCC TTC TTC AGC AGC AAC GAC CAA CCA CAG TCC TTG AAT TTT GGG GGC ATC GGG ATG GTG ATT GGG CAC GAG  
630  
ile thr his gly phe asp asp asn gly arg arg asn phe asp lys asn gly asn met leu asp trp trp ser asn phe ser ala arg his phe  
1801 ATC ACA CAC GGC TTT GAT GAT AAT GGT CGT AAC TTT GAC AAG AAC GGC AAC ATG CTG GAC TGG TGG AGT AAC TTC TCG GCC CGG CAC TTC  
660  
gln gln gln ser gln cys met ile tyr gln tyr gln gln tyr gln ala asp asn gln asn val asn gly phe ser thr leu  
1891 CAA CAG CAG TCG CAA TGC ATG ATC TAT CAG TAC GGC AAC TTC TCT TGG GAA CTA GCA GAC AAC CAG AAT GTG AAC GGA TTC AGT ACC CTC  
690  
gly glu asn ile ala asp asn gly gly val arg gln ala tyr lys ala tyr leu arg trp leu ala asp gly lys asp gln arg leu  
1981 GGG GAG AAC ATT GCC GAC AAC GGA GGT GTG CGA CAG GCA TAC AAG GCT TAC CTA CGG TGG CTG GCT GAT GGC GGC AAA GAT CAG CGA CTG  
720  
pro gly leu asn leu thr tyr ala gln leu phe phe ile asn tyr ala gln val trp cys gly ser tyr arg pro glu phe ala val gln  
2071 CCG GGA CTG AAC CTG ACC TAT GCC CAG CTT TTC TTC ATC AAC TAT GCC CAG GTG TGG TGT GGG TCC TAT AGG CCG GAG TTC GCC GTC CAG  
750  
ser ile lys thr asp val his ser pro leu lys tyr arg val leu gly ser leu gln asn leu pro gly phe ser glu ala phe his cys  
2161 TCC ATC AAG ACG GAC GTC CAC AGT CCT CTT AAG TAC AAG GTG CTG GGC TCA CTA CAG AAC CTG CCA GGC TTC TCT GAG GCA TTC CAC TGC  
765  
pro arg gly ser pro met his pro met lys arg cys arg ile trp \*\*\*  
2251 CCA CGA GGC AGC CCC ATG CAC CCC ATG AAG CGA TGT CGC ATC TGG TAG CCAAGGCTGAGCTATGCTGGGCCCCACGCCGCCACCCAGAGGCTTCGGGAATG  
2354 GTGTAGCTGGCAGAGATGTGCAGGTCTTTGCCCTGAGGCCACCGGAGCCACCCAGCCCTCCGGCCCGCCAGCTAGAGTGTAGCCACCCGCCACCCCGGGATGAGTGGTGCCGGTC  
2473 CTGGCCCCCTCAGGCCAGTGAGGGTCAGCAGCCAGGAAGAGCAGTCAGCTGCCCTTCACCCCTCTCCATAGTGTGTGGCTAAATGTTCTCGAGCTTCAGACTTGAGCTAAGTAAACGC  
2925 TTC

715 - 3 (cont'd)



8/22

## Sequence of NL-2 cDNA from humans

1 GTG GGG met val glu ser ala gly arg ala gly gln lys arg pro gly phe leu glu gly leu leu leu leu leu val thr 28  
 91 GCT GCC CTG GGC TTG GGT GTC CTC TAC GCC GAC CCG AGA GGG AAG CAG CTG CCA CGC CTT GCT AGC CGG CTG TGC TTC TTA CAG glu 58  
 181 GAG AGG ACC TTT GTA AAA CGA AAA CCC CGA GGG ATC CCA GAG GCC CAA GAG GTG GTC ACC ACC CCT GGC TGC GTG ATA GCA 88  
 271 GCC AGG ATC CTC CAG AAC ATG GAC CCG ACC ACC GAA CCG TGT GAC GAC TTC TAC CAG TTT GCA TGC GGA GGC TGG CTG CGC 118  
 361 GTG ATC CCT GAG ACC AAC TCA AGA TAC AGC ATC TTT GAC GTC CTC CGC GAC GAG CTG GAG GTC ATC CTC AAA CCG GTG CTG GAG AAT TCG 148  
 451 ACT GCC AAG GAC CCG CCG GCT GTG GAG AAG GCC AAG GAC CCG TCC TGC ATG AAC CAG AGT GTG ATA GAG AAG CGA GGC TCT CAG 178  
 541 CCC CTG GAC ATC TTG GAG GTG val glu val val ala met asp arg trp pro val ala met asp arg trp asn glu thr val gly leu glu trp glu leu glu 208  
 631 CGG CAG CTG GCG CTG ATG AAC TCA CAG TTC AAG CCG GTC CTC ATC GAC CTC TTT CAG CAG CAG CAG CAG CAG CAG CAG CAG CAG CAG CAG CAG 238  
 721 ATC ATC TAC ATA GAC CAG CCC ACC TTG GGC ATG CCC TCC CGA GAG TAC TAC TTC AAC GGC GGC AGC AAC CGG AAG GTG CGG GAA GCC TAC 268  
 811 CTG CAG TTC ATG GTG TCA GTG GCC ACC TTT GAG CCG GAT GCA AAC CTG CCC AGG GAC AGC TGC CTG GTG CAG GAG GAC ATG GTG 298  
 328

---

 4

9/22

val leu glu leu glu thr gln thr gln ala lys ala thr val pro gln glu glu arg his asp val ile ala leu tyr his arg met gly leu  
901 GTT CTG GAG CTG GAG ACA CAG CTG GCC AAG GCC AAG GGC ACC GTC ATA CAC GAG AGA CAC CAC GAG CTG TTT TAC CAC CGG ATG GGA CTG  
glu glu leu gln ser gln phe gln phe lys leu lys gln phe leu phe ile gln thr val leu ser ser val lys ile lys leu  
991 GAG GAG CTG CAA AGC CAG TTT GGC CTG AAG GGA TTT AAC TGG ACT CTG TTC ATA CAA ACT GTG CTA TCC TCT GTC AAA ATC AAG CTG  
pro asp glu glu val val val tyr gly ile pro tyr leu gln asn leu glu asn ile ile asp thr tyr ser ala arg thr ile gln asn  
1081 CCA GAT GAG GAA GTG GTC TAT GGC ATC CCC TAC CTG CAG AAC CTT GAA AAC ATC ATC GAC ACC TAC TCA GCC AGG ACC ATA CAG AAC  
tyr leu val trp arg leu val leu asp arg ile gly ser leu ser gln arg phe lys asp thr arg val asn tyr arg lys ala leu phe  
1171 TAC CTG GTC TGG CGC CTG GTG CTG GAC CGC ATT GGT AGC CTA AGC CAG AGA TTC AAG GAC ACA CGA GTG AAC TAC CGC AAG GCG CTG TTT  
gly thr met val glu glu val arg trp arg glu cys val gly tyr val asn ser asn met glu asn ala val gly ser leu tyr val arg  
1261 GGC ACA ATG GTG GAG GAG GTG CGC TGG CGT GAA TGT GTG GGC TAC GTC AAC AGC AAC ATG GAG AAC GCC GTG GGC TCC CTC TAC GTC AGG  
glu ala phe pro gly asp ser lys ser met val arg glu leu ile asp lys val arg thr val phe val val GTG TTT GTG GAG ACG CTG GAC GAG CTG GGC  
1351 GAG GCG TTC CCT GGA GAC AGC ATG GTC AGA GAA CTC ATT GAC AAG GTG CCG ACA GTG TTT GTG GAG ACG CTG GAC GAG CTG GGC  
trp met asp glu glu ser lys lys lys ala gln glu lys ala met ser ile arg glu gln ile gly his pro asp tyr ile leu glu glu  
1441 TGG ATG GAC GAG TCC AAC AAG AAG GCG CAG GAG AAG GCC ATG AGC ATC CGG GAG CAG ATC GGG CAC CCT GAC TAC ATC CTG GAG GAG  
met asn arg arg leu asp glu glu tyr ser asn leu asn phe ser glu asp leu tyr phe glu asn ser leu gln asn leu lys val gly  
1531 ATG AAC AGG CGC CTG GAG GAG TAC TCC AAT CTG AAC TTC TCA GAG GAC CTG TAC TTT GAG AAC AGT CTG CAG AAC CTC AAG GTG GGC  
ala gln arg ser leu arg lys leu arg glu lys val asp pro asn leu trp ile ile gly ala ala val val asn ala phe tyr ser pro  
1621 GCC CAG CGG AGC CTC AGG AAG CTT CGG GAA AAG GTG GAC CCA AAT CTC TGG ATC ATC GGG CCG GCG GTG GTC AAT CGG TTC TAC TCC CCA  
asn arg asn gln ile val phe pro ala gly ile leu gln pro pro phe phe ser lys glu gln pro gln ala leu asn phe gly gly ile  
1711 AAC CGA AAC CAG ATT GTA TTC CCT GCC GGG ATC CTC CAG CCC CCC TTC TTC ACC AAG GAG CAG CCA CAG GCC TTG AAC TTT GGA GGC ATT  
628

Fr - 4 (cont'd)

10/22

gly met val ile gly his glu ile thr his gly phe asp asp asn gly arg asn phe asp lys asn gly asn met met asp trp trp ser  
1801 GGG ATG GTG ATC GGG CAC GAG ATC ACG CAC GGC TTT GAC GAC AAT GGC AAT GGC AAG AAT GGC AAC ATG ATG GAT TGG TGG AGT 658

asn phe ser thr gln his phe arg glu gln ser glu cys met ile tyr gln tyr gly asn tyr ser trp asp leu ala asp glu gln asn  
1891 AAC TTC TCC ACC CAG CAC TTC CGG GAG CAG TCA GAG TGC ATG ATC TAC TAC GGC AAC TAC TCC TGG GAC CTG GCA GAC GAA CAG AAC 688

val asn gly phe asn thr leu gly glu asn ile ala asp asn gly gly val arg gln ala tyr leu lys trp met ala glu  
1981 GTG AAC GGA TTC AAC ACC CTT GGG GAA AAC AAT GCT GAC AAC GGA GGG GTG CCG CAA GCC TAT AAG GCC TAC CTC AAG TGG ATG GCA GAG 718

gly gly lys asp gln gln leu pro gly pro gln ser ile lys thr asp leu thr his glu gln gln phe phe ile asn tyr ala gln val trp cys gly ser tyr  
2071 GGT GGC AAG GAC CAG CAG CTG CCC GGC ATC AAG AAG ACA GAC GAC CAT ACC CAC GTC CAC AGT CCC CAG CAG CTC TTC TAC TAT GCC CAG GTG TGG TGC GGG TCC TAC 748

arg pro glu phe ala ile gln ser ile lys thr asp val his ser pro lys val leu gly ser leu gln asn leu ala ala  
2161 CGG CCC GAG TTC GCC ATC CAA TCC ATC AAG AAG ACA GAC GAC GTC CAC AGT CCC AAG GAG TAC AGG GTA CTG GGG TCG CTG CAG AAC CTG GCC GCC 770

phe ala asp thr phe his cys ala arg gly thr pro met his pro lys glu arg cys arg val trp ter  
2251 TTC GCA GAC ACG TTC CAC TGT GCC CGG GGC ACC CCC ATG CAC CCC AAG GAG CGA TGC CGC GTG TGG TAG CCA AGG CCC TGC CGC GCT GTG

2341 CGG CCC ACG CCC ACC CGC TGC TCG GAG GCA TCT GTG CGA AGG TGC AGC TAG CGG CGA CCC AGT GTA CGT CCC GCC CCG GCC AAC CAT GCC

2431 AAG CCT GCC TGC CAG GCC TCT GCG CCT GGC CTA GGG TGC AGC CAC CTG CCT GAC ACC CAG GGA TGA GCA GTG TCC AGT GCA GTA CCT GGA

2521 CCG GAG CCC CCT TCA CAG ACA CCC GCG GGC CTC AGT GCC CCC GTC ACA ACT CTG TAG AGA CAA TCA ACT GTG TCC TGC CCA CCC TTC AAG

2611 GTG CAT TGT CTT CCA GTA TCT ACA GCT TCA GAA CTT GAG CTA AGT AAA TGC TTT CAA AGA AAA AAA

Free - 4 (cont'd)

Sequence of NL-3 cDNA from human

11/22

09/913329

FOF230" 52221650

12/22

352 ile thr val ser glu tyr asp asp leu arg arg asp val ser ser met tyr asn lys val thr leu gly gln leu gln lys ile thr pro  
 1171 ATC ACT GTG TCA GAG TAT GAC GAC CTA GAC CGA GAT GTC AGC TCC ATG TAC AAC AAG GTG ACG CTG GGG CAG CTG CAG AAG ATC ACC CCC  
 382 his leu arg trp lys trp leu leu asp gln ile phe gln glu asp phe ser glu glu glu val val leu leu ala thr asp tyr met  
 1261 CAC TTG CGG TGG AAG TGG CTG CTA GAC CAG ATC TTC CAG GAG GAT TCA GAG GAA GAG GAG GTG GTG CTG CTG GCG ACA GAC TAC ATG  
 412 gln gln val ser gln leu ile arg ser thr pro his arg val leu val his asn tyr leu val val val leu ser glu his  
 1351 CAG CAG GTG TCG CAG CTC ATC CGC TCC ACA CCC CAC CGG GTC CTG CAC AAC TAC CTG GTG GTG GTC CTG AGT GAA CAC  
 442 leu ser pro pro phe arg glu ala leu his glu leu ala gln glu met glu gly ser asp lys pro gln leu ala arg val cys leu  
 1441 CTG TCC CCG CCA TTC CGT GAG GCA CTG CAC GAG CTG GCA CAG CAG GAG ATG GAG GGC AGC GAC AAG CCA CAG GAG CTG GCC CGG GTC TGC TTG  
 472 gly gln ala asn arg his phe gly met ala leu gly ala leu phe val his glu his phe ser ala ala ser lys ala lys val gln gln  
 0 1531 GGC CAG GCC AAT CGC CAC TTT GGC ATG GCG CTT GGC GCC CTC TTT GTA CAT GAG CAC TTC TCA GCT GCC AGC AAA GCC AAG GTG CAG CAG  
 502 leu val glu asp ile lys tyr ile leu glu gly gln arg leu glu glu glu met asp ala glu thr arg ala ala arg ala lys  
 1621 CTA GTG GAA GAC ATC AAG TAC ATC CTG GGC CAG CGC CTG GAG CAG CTG GAG TGG ATG GAC TGG ATG GAC ACC AGG GCT GCT CGG GCC AAG  
 532 leu gln tyr met met val met val gly tyr pro asp phe leu leu lys pro asp ala val asp lys glu tyr glu phe glu val his glu  
 1711 CTC CAG TAC ATG ATG GTG ATG GTC GGC TAC CCG GAC TTC CTG CTG CAG CAG CCG GAT GCT GCT GAG TAT GAG TTT GAG GTC CAT GAG  
 562 lys thr tyr phe lys asn ile leu asn ser ile arg phe ser ile gln leu ser val lys lys ile arg gln glu val asp lys ser thr  
 1801 AAG ACC TAC TTC AAG AAC ATC TTG AAC AGC ATC CGC TTC ACC ATC CAG CTC TCA GTT AAG AAG ATT CGG CAG GAG GTG GAC AAG TCC ACG  
 592 trp leu leu pro pro gln ala leu asn ala tyr tyr leu pro asn lys asn gln met val phe pro ala gly ile leu gln pro thr leu  
 1891 TGG CTG CTC CCC CCA CAG GCG CTC AAT GCC TAC TAT CTA CCC AAC AAG AAC CAG ATG GTG TTC CCC GCG GGC ATC CTG CAG CCC ACC CTG  
 622 tyr asp pro asp phe pro gln ser leu asn tyr gly gly gly ile gln thr ile ile gln his glu leu thr thr asp asp trp gly  
 1981 TAC GAC CCT GAC TTC CCA CAG TCT CTC AAC TAC GGC GGC ATC GGC ACC ATC ATT GGA CAT GAG CTG ACC CAC GGC TAC GAC GAC TGG GGG  
 652

---

 Trp - 5 (cont'd)

09/913329

13/22

2071 gly gln tyr asp arg ser gly asn leu leu his trp trp thr glu ala ser tyr ser arg phe leu arg lys ala glu cys ile val arg  
 GGC CAG TAT GAC CGC TCA GGC AAC CTG CTG CAC TGG TGG ACG GAG GCC TCC TAC AGC CGC TTC CTG CGA AAG GCT GAG TGC ATC GTC CGT  
 682  
 2161 leu tyr asp asn phe thr val tyr val tyr asn gln arg val asn gly lys his thr leu gly glu asn ile ala asp met gly gly leu lys leu  
 CTC TAT GAC AAC TTC ACT GTC TAC AAC CAG CGG GTG AAC GGG AAA CAC ACG CTT GGG GAG AAC ATC GCA GAT ATG GGC GGC CTC AAG CTG  
 712  
 2251 ala tyr his ala tyr gln lys trp val arg glu his gly pro glu his pro leu pro arg leu lys tyr thr his asp gln leu phe phe  
 GCC TAC CAC GCC TAT CAG AAG TGG CTG CGG GAG CAC GGC CCA GAG CAC CCA CTT CCC CGG CTC AAG TAC ACA CAT GAC CAG CTC TTC TTC  
 742  
 2341 ile ala phe ala gln asn trp cys ile lys arg arg ser gln ser ile tyr leu gln val leu thr asp lys his ala pro glu his tyr  
 ATT GCC TTT GCC CAG AAC TGG TGC ATC AAG CGG CGG TCG CAG TCC ATC TAC CTG CAG GTG CTG ACT GAC AAC CAT GCC CCT GAG CAC TAC  
 772  
 2431 arg val leu gly ser val ser gln phe glu glu phe gly arg val leu his cys pro lys val ser pro met asn pro ala his lys cys  
 AGG GTG CTG GGC AGT GTG TCC CAG TTT GAG GAG TTT GGC CGG GTT TTA CAC TGT CCA AAG GTC TCA CCC ATG AAC CCT GCC CAC AAG TGT  
 775  
 ser val trp ter  
 2521 TCC GTG TGG TGA CCC TGG CTG CCC GGC TGC ACB CCC CCA CTG CCC CCG CAC GAA TCA CCT CCT GGT TAC CGG GGC AGG CAT GCA CCC  
 2611 GGT GCC AGC CCC GCT CTG GGC ACC ACC TGC CTT CCA GCC CCT CCA GGA CCC GGT CCC CCT GCT GCC CCT CAC TTC AGG AGG GGC CTG GAG  
 2701 CAG GGT GAG GCT GGA CTT TGG GGG GCT GTG AGG GAA ATA TAC TGG GGT CCC CAG ATT CTG CTC TAA GGG GGC CAG ACC CTC TGC CAG GCT  
 2791 GGA TTG TAC GGG CCC CAC CTT CGC TGT GTT CTT GCT GCA AGT CTG GTC AAA TAA ATC ACT GCA CTG TTA AAA AAA AAA AAA

~~13/22~~ - 5 (cont'd)

10/23/00 000000

09/913329

14/22

## Sequence comparison between NEP, NL1, NL2 and NL3

	1	10	20	30	40
NEP-HUM	MG.....	KSESQMDITDINTPKPKKKQ	RWTPLEISLSVLVLL..	LTII...AV	
	*		*	*	*
NL1-MOU	MV.....	ERAGWCRKKS	PGFVEYGLMVLLLLLL	GAIVTLG.V..	FYSI.GKQL
	**	* **	* **	* **	****
NL2-HUM	MV.....	ESAGRAGQKR	PGFLEGGLLLLLL	LVTAALVALGV..	YADRRGKQL
	*		*	*	*
NL3-HUM	MEPPYSLTAHYDEFQ	EVKYVSR	CAGGARGASLPP	PGFPLGAARSAT	GARSGLPRWNRREV

	50	60	70
NEP-HUM	TMIA.....	LYATYDD.....	GICKSSDCIKSAARLIQ.NMDATT
	*	*	** * ** *
NL1-MOU	PLLTSL....	LHFSWDERTVVKR...ALRDSSLKSDICTTPSCVIAAARILE.NMDQSR	
	* * *	* * *	* * * * * *
NL2-HUM	PRLASR....	LCFLQEERTFVKR	KPRGIPEAQEVSEVCTTPGCVIAAARILQ.NMDPTT
	*	*	* * * * *
NL3-HUM	CLLSGLVFAAGLCAIL	AAMLALKYLGPVAAGGGAC	PEGCPEKAFARAARFLAANLDASI

	80	90	100	110	120	130
NEP-HUM	EPCTDFFKYACGGWLKRN	VIPETSSRYGNFDILRDELEVVLK	DVLQEPKTEDIVAVQ.KA			
	** *	*****	*****	*****	*****	** *
NL1-MOU	NPCENFYQYACGGWLRHH	VIPETNSRYSVFDILRDELEVILKGVLEDSTS	QHRPAVE.KA			
	** *	*****	*****	*****	*****	** *
NL2-HUM	EPCDDFYQFACGGWLR	RRHVIPETNSRYSIFDVL	RDELEVILKAVLENSTAKDRPAVE.KA			
	** *	*****	*	*	*	*
NL3-HUM	DPCQDFYSFACGGWLR	RHAIPDDKLT	YGTIAAIGE	QNEERLRRL	LARPGGGPGGAAQRKV	

	140	150	160	170	180	190
NEP-HUM	KALYRSCINESAIDSRGGE	PLLKLLPDIYGWPVATENWEQ	KYGASWTAEKAI	AQLNSKYG		
	* * * * *	* * *	* * *	* * *	* * *	* * *
NL1-MOU	KTLYRSCMNQSVIEKRD	SEPLLSVLKMGVGPVAMDKWNETMGLKWELERQLAVLNSQFN				
	*****	*****	*****	*****	*****	*****
NL2-HUM	RTLYRSCMNQSVIEKRG	SQPLLDILEVVGWPVAMDRWNETVGLEWELERQLALMNSQFN				
	* * *	* * *	* * *	* * *	* * *	* * *
NL3-HUM	RAFFRSCLDMREIERL	GPRPMLEVI	EDCGGWDLGGAEERPGVAARWDLNRLLYKAQGVYS			

	200	210	220	230	240	250
NEP-HUM	KKVLINLFGVTDDKNSVNH	VIHIDQPRGLPSRDYYECTGIYKEACTAYVDFMISVARLI				
	*** **	*** **	*** **	*** **	*** **	*** **
NL1-MOU	RRVLIDLFIWNDDQNSSRH	VIYIDQPTLGMP	SREYYFQEDNNHKVRKAYLEFMTSVATML			
	*****	*****	*****	*****	*****	*****
NL2-HUM	RRVLIDLFIWNDDQNSSRH	IIYIDQPTLGMP	SREYYFNNGSNRKVREAYLQFMVSVATLL			
	* * *	* * *	* * *	* * *	* * *	* * *
NL3-HUM	AAALFSLTVSLDDR	NSSRYVIRIDQDGLTLP	PERTLYLAQDEDSE..KVLAAYRVFMERVL			

09/913329

15/22

260 270 280 290 300 310  
 NEP-HUM RQEERLPIDENQLALEMKNVMELEKEIANATAKP..EDRNDPMLLYNKMTLAQIQNNFSL  
 \* \* \* \* \*  
 NL1-MOU RKDQNLKESAMVREEMAIEVLELETHLANATVPQ..EKRHDVTALYHRMDLMELQERFGL  
 \* \* \* \* \*  
 NL2-HUM REDANLPRDSCLVQEDMVQVLELETQLAKATVPQ..EERHDVIALYHRMGLEELQSQFGL  
 \* \* \* \* \*  
 NL3-HUM SL...LGADAV..EQKAQEILQVEQQLANITVSEYDDLRRDVSSMYNKVTLGQLQKITP.

320 330 340 350 360 370  
 NEP-HUM EINGKPFPSWLNFTNEIMSTVNISITNEEDVVVYAPEYLTCLKPILTKYSARDLQNLMSWR  
 \* \* \* \* \*  
 NL1-MOU ...KGFNWTLFIQNVLSSEVELEFPDEEVVVGIPYLENLEDIIDSYSARTMQNYLVWR  
 \* \* \* \* \*  
 NL2-HUM ...KGFNWTLFIQTVLSSVVKIKLLPDEEVVVGIPYLQNLNIIDTYSARTIQNYLVWR  
 \* \* \* \* \*  
 NL3-HUM ....HLRWKWLLDQIF...QEDFSEEEVVLLATDYMQQVSQLIRSTPHRVLHNYLVWR

380 390 400 410 420 430  
 NEP-HUM FIMDLVSSLSRTYKESRNAFRKALYGTTSSETATWRRCANVNGNMENAVGRLYVEAAAFAG  
 \* \* \* \* \*  
 NL1-MOU LVLDRIGSLSQRFKEARVDYRKALYGTTVVEEVRWRECVSYVNSNMESAVGSLYIKRAFSK  
 \* \* \* \* \*  
 NL2-HUM LVLDRIGSLSQRFKDTRVNYRKALFGTMVEEVRWRECVGYVNSNMENAVGSLYVREAFPG  
 \* \* \* \* \*  
 NL3-HUM VVVVLSEHLSPPPFREALHELAQEMEGSDKPQELARVCLGQANRHFGLALFVHEHESA

440 450 460 470 480 490  
 NEP-HUM ESKHVVEDLIAQIREVFIQTLDDLTWMDAETKKRAEEKALAIKERIGYPDDIVSNDNK.L  
 \* \* \* \* \*  
 NL1-MOU DSKSTVRELIEKIRSVFVDNLDELNWMDEESKKKAQEKAMNIREQIGYPDYILEDNKHL  
 \* \* \* \* \*  
 NL2-HUM DSKSMVRELIDKVRTVFVETLDELGWMDEESKKKAQEKAMSIREQIGHDPDYILEEMNRL  
 \* \* \* \* \*  
 NL3-HUM ASKAKVQQLVEDIKYILGQRLEELDWMDAETRAAARAKLQYMMVMVGYPDFLLKPPDA..V

500 510 520 530 540 550  
 NEP-HUM NNEYLELNYKEDEYFENIIQNLKFSQSKQLKKLREKVDKDEWISGAAVVNAFYSSGRNQI  
 \* \* \* \* \*  
 NL1-MOU DEEYSSLTFYEDLYFENGLQNLKNNQAQRSLKKLREKVDQNLWIIGAAVVNAFYSPNRNQI  
 \* \* \* \* \*  
 NL2-HUM DEEYSLNLFSEDLFYFENSLQNLKVGQAQRSLRKLREKVDPNLWIIGAAVVNAFYSPNRNQI  
 \* \* \* \* \*  
 NL3-HUM DKE.YEFVHEKTYFKNILNSIRFSIQLSVKKIRQEVDKSTWLLPPQALNAYYLPNKNQM

FILE - 6 (cont'd)

09/913329-6230-660




16/22

	560	570	580	590	600	610
NEP-HUM	VFPAGILQPPFFSAQQSNSLNYGGIGMVIGHEITHGFDDNGRNFHKDGDLDVWWTQQSAS					
	*****	*	***	*****	*	***
NL1-MOU	VFPAGILQPPFFSKDQPQSLNFGGIGMVIGHEITHGFDDNGRNFDKNGNMLDWWSNFSAR					
	*****	***	*****	*****	*****	*****
NL2-HUM	VFPAGILQPPFFSKEQPQALNFGGIGMVIGHEITHGFDDNGRNFDKNGNMDWWSNFSSTQ					
	*****	***	***	***	***	***
NL3-HUM	VFPAGILQPTLYDPDFPQSLNYYGGIGTIIGHELTHGYDDWGGQYDRSGNLLHWWTEASYS					

	620	630	640	650	660	670
NEP-HUM	NFKEQSQCMIYQYGNFSWDLAGGQHLNGINTLGENIADNGGLGQAYRAYQNYIKKNGEEK					
	*	*****	*	*****	*****	*
NL1-MOU	HFQQQSQCMIYQYGNFSWELADNQNVDNGFSTLGENIADNGGVRQAYKAYLRWLADGGKDQ					
	**	*****	***	*****	*****	*****
NL2-HUM	HFREQSECMYQYGNYSWDLADEQNVDNGFNTLGENIADNGGVRQAYKAYLKWMAEGGKDQ					
	*	**	*	***	*****	***
NL3-HUM	REFLRKAECIVRLYDNFT...VYNQVRVNGKHTLGENIADMGGLKLAYHAYQKWVREHGPEH					

	680	690	700	710	720	730
NEP-HUM	LLPGLDLNHNKQLFFLNFAQVWCGTYRPEYAVNSIKTDVHSPGNFRIIGTLQNSAEFSEAF					
	****	*	*****	*****	*	*****
NL1-MOU	RLPGLNLTYAQLFFINYAQVWCGSYRPEFAVQSIKTDVHSPLKYRVLGSLQNLPGFSEAF					
	****	**	*****	*****	*****	*
NL2-HUM	QLPGLDLTHEQLFFINYAQVWCGSYRPEFAIQSIKTDVHSPLKYRVLGSLQNLAAFADTF					
	**	*	*****	*****	*****	*
NL3-HUM	PLPRLKYTHDQLFFIAFAQNWCIKRRSQSIYLOVLTDKHAPEHYRVLGVSQSFEFGRVL					



	740	750
NEP-HUM	HCRKNSYMNPEKKCRVW	
	**	*****
NL1-MOU	HCPRGSPMHPMKRCRIW	
	**	*****
NL2-HUM	HCARGTPMHPKERCRVW	
	**	*****
NL3-HUM	HCPKVSPMNPAAHKCSVW	

 (cont'd)

PCT/CA00/00147

17/22

# NL1 in the TESTIS



TESTIS

18/22

Expression of PEX and NL-3 in normal and Hyp mouse embryos






FIG. 1

19/22

# NL3 in the BRAIN



09913329.082101

20/22

# Structure and expression of NL-1







FIG. 10

21/22

Enzymatic activity of NL-1



Degradation of [ $^3\text{H}$ ]Tyr, D-Ala<sub>2</sub>, Leu<sub>5</sub>-enkephalin

TABLE 11

22/22

MOCK NL-3 CTL NL-3




FIG. 12

**RULE 63 (37 C.F.R. 1.63)**  
**INVENTORS DECLARATION FOR PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

As a below named inventor, I hereby declare that my residence, mailing address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**NEW METALLOPROTEASES OF THE NEPRILYSIN FAMILY**

the specification of which (check applicable box(es)):

☒ is attached hereto  
☐ was filed on \_\_\_\_\_ as U.S. Application Serial No. \_\_\_\_\_ (Atty Dkt. No. 163-12987.17)

☒ was filed as PCT International application No. PCT/CA00/00147 on February 11, 2000  
and (if applicable to U.S. or PCT application) was amended on \_\_\_\_\_

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose to the Patent Office all information known to me to be material to patentability as defined in 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Priority Foreign Application(s):	Application Number	Country	Day/Month/Year Filed
	2,260,376	Canada	11/02/1999

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

Application Number	Date/Month/Year Filed

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international applications listed above or below:

Prior U.S./PCT Application(s):	Application Serial No.	Day/Month/Year Filed	Status: patented pending, abandoned


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And on behalf of the owner(s) hereof, I hereby appoint NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 8<sup>th</sup> Floor, Arlington, VA 22201-4714, telephone number (703) 816-4000 (to whom all communications are to be directed), and the following attorneys thereof (of the same address) individually and collectively owner's/owners' attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Larry S. Nixon, 25640; Arthur R. Crawford, 25327; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Besha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Jeffrey H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnam, Jr. 29366; Mary J. Wilson, 32955; J. Scott Davidson, 33489; Alan M. Kagen, 36178; Robert A. Molan, 29834; B. J. Sadoff, 36663; James D. Berquist, 34776; Updeep S. Gill, 37334; Michael J. Shea, 34725; Donald L. Jackson, 41090; Michelle N. Lester, 32331; Frank P. Presta, 19828; Joseph S. Presta, 35329; Joseph A. Rhoa, 37515; Raymond Y. Mah, 41426; Chris Comuntzis, 31097. I also authorize Nixon & Vanderhye to delete any attorney names/numbers no longer with the firm and to act and rely solely on instructions directly communicated from the person, assignee, attorney, firm, or other organization sending instructions to Nixon & Vanderhye on behalf of the owner(s).

1. Inventor's Signature: [Signature] Date: 8/8/01  
Inventor: Luc DESGROSEILLERS CANADA  
(first) (last) (citizenship)  
Residence: (city) St-Basile-le-Grand CA MI (state/country) Québec/Canada  
Mailing Address: 18 des Geais Bleus  
(Zip Code) J3N 1L1

2. Inventor's Signature: [Signature] Date: 8/08/01  
Inventor: Guy BOILEAU CANADA  
(first) (last) (citizenship)  
Residence: (city) Brossard CA MI (state/country) Québec/Canada  
Mailing Address: 7645 Malherbe  
(Zip Code) J4Y 1E6



United States Patent & Trademark Office  
Office of Initial Patent Examination - Scanning Division



Application deficiencies found during scanning:

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☒ Scanned copy is best available. of Drawings.

SCANNED, # 2